¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/31 ¤U¤È 04:33:44
²Ä 6083 ½g¦^À³
|
Lebrikizumab °ÝÃD¬O¤£Ã©w, ¨âÓADÁ{§É·|¦³«Ü¤j®t²§. ý³Ý¤T´Á´N¬O¤@ÓÁ{§ÉP<0.05//¥t¤@ÓP>0.05
In trial 1, the primary outcome was met in 43.1% of 283 patients in the lebrikizumab group and in 12.7% of 141 patients in the placebo group (P<0.001)
In trial 2, the primary outcome was met in 33.2% of 281 patients in the lebrikizumab group and in 10.8% of 146 patients in the placebo group (P<0.001)
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
www.nejm.org/doi/full/10.1056/NEJMoa2206714
RESULTS In trial 1, the primary outcome was met in 43.1% of 283 patients in the lebrikizumab group and in 12.7% of 141 patients in the placebo group (P<0.001); an EASI-75 response occurred in 58.8% and 16.2%, respectively (P<0.001).
In trial 2, the primary outcome was met in 33.2% of 281 patients in the lebrikizumab group and in 10.8% of 146 patients in the placebo group (P<0.001); an EASI-75 response occurred in 52.1% and 18.1%, respectively (P<0.001).
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/31 ¤U¤È 12:23:20
²Ä 6082 ½g¦^À³
|
CEO ³Å«i»{¬°°ª¾¯¶qIGA,0,1Àø®Ä¦Ü¤Ö44%.vs 15%(¹ï·Ó组)
¥Ø«e¥i¥H½T©wªº¬O Àø®Ä(ªvÀø®ÄªG)Ĺ¹LLebrikizumab¤F
µ¥7¤ëªì¸Ñª¼¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/31 ¤W¤È 09:48:55
²Ä 6081 ½g¦^À³
|
7¤ëªì¤½§iªºASLSN004 2b¸Ñª¼¼Æ¾Ú
¥«È¼ÒÀÀ¡G Y ¤@¡BIGA0,1>54%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù31¡D25¬ü¤¸¡D ¶Ò资»ù25¬ü¤¸ ¥«È25¬ü¤¸x4¸U¤dªÑ=10»õ¬ü¤¸
¤G¡BIGA0,1=45%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù15¡ã20¬ü¤¸¡D¶Ò资»ù12¡ã16¬ü¤¸ ¥«È4.8¡ã6.4»õ¬ü¤¸¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/31 ¤W¤È 09:33:03
²Ä 6080 ½g¦^À³
|
¨p¶Ò2000¸U¬ü¤¸¤Î8000¸U¬ü¤¸»{ªÑÅvªº¨Ì¾Ú¡Bªñ80%x300¤H 2b ªº¥¼¸Ñª¼x16¶gªvÀø«áªº¼Æ¾Ú¡D
CEO ³Å«i»{¬°°ª¾¯¶qIGA,0,1Àø®Ä¦Ü¤Ö44%.vs 15%(¹ï·Ó组)
¥i«H«×°ª!
¦³1/3ªºÁ{§É¤¤¤ß±¾ASLN ¡B¦h©â¤@¨Ç¦å¡B§Y¥i¤ÀªR¦å²G¤¤ªºÃĶq¦s¶q¡B¥i¦³®Ä预测¬ÛÃö¼Æ¾Ú?!(¤£ª¾¬O§_¦p¦¹°õ¦æ?)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/3/31 ¤W¤È 09:22:51
²Ä 6079 ½g¦^À³
|
¥i§_½Ð¤Ñ©R¤j¤ÀªR¤@¤U ¤U±³oӼƾڪº»ùÈ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/31 ¤W¤È 08:09:33
²Ä 6078 ½g¦^À³
|
H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) - March 30, 2023
journey.ct.events/view/61f3dfa3-80fd-4977-954c-981a5ef92fda
CEO ³Å«i¦^µªªº²Ä¤TÓ°ÝÃD¡D
¥D«ù¤H¡G³¯¤ÀªR®v(µØ¤H¡B¥Íª«³Õ¤h) °Ý¡G½Í½Í7¤ë¥÷n¸Ñª¼ªº2b AD Á{§É! µª¡G¡K预´Á°ª¾¯¶qªºIGA0,1Àø®Ä¦Ü¤Ö44% ¹ï·Ó组¬ù15%....
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/30 ¤U¤È 10:59:46
²Ä 6077 ½g¦^À³
|
ASLN CEO ¥¿¨üH.C.WAINWRIGHT& CO.¨é°Ó³¯¥ý¥Í³X°Ý¡B
7¤ëªì 004 2b¸Ñª¼
CEO预´ÁIGA0,1 400mgxQ2WÀø®Ä¦Ü¤Ö(Min.)44%vs15%(¹ï·Ó组) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 |
µoªí®É¶¡:2023/3/26 ¤U¤È 02:29:12
²Ä 6076 ½g¦^À³
|
¤Ñ©R¤jºâ¥X¨Óªº¥§¡»ù®æÀ³¸Ó¬O¥]§t¤§«áªº»{ªÑÅvÃÒ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 |
µoªí®É¶¡:2023/3/26 ¤U¤È 02:17:53
²Ä 6075 ½g¦^À³
|
¥X°âªÑ东ªº关¨t °£¤Wªí脚ª`¤¤¥t¦³©ÜÅS¦}¦p¤U©Òz¥~¡A¥X°âªÑ东¤¤没¦³¥ô¦ó¤@个¤H¦b过¥h¤T¦~¤¤ü®¥ô过§Ú们ªº职¦ì¡B职务©Î¨ä¥L«n关¨t¡C 2023¦~2¤ë24¤é¡A§Ú们ÉO¥X°âªÑ东©Î购买¤è签订¤F单¦ì购买协议¡A®ÚÕu该协议¡A§Ú们¦P·N¦V购买¤è¥X°â¡]i¡^59,957,865ªÑ´¶³qªÑ¡]©Î¬Û当¤_2,398,314 ADS¡^©M¡]ii¡^52,401,685ªÑ´¶³qªÑ¡A¥i¦æ¨Ï预¥ý资§Uªº认ªÑ权证¡]©Î¬Û当¤_2,096,067 ADS¡^¡Aɲ®æ为¨CªÑ´¶³qªÑ0.178¬ü¤¸¡]©Î¨CADS 4.45¬ü¤¸¡^©M¨C个预¥ý资§Uªº认ªÑ权证4.4475¬ü¤¸¡C¨p¶Ò结§ô¤_2023¦~2¤ë27¤é¡C §@为¨p¶Òªº¤@³¡¤À¡A购买¤è还获±o¤F两个¥i¦æ¨Ïªº认ªÑ权证¡A总¦@¥i¦æ¨Ï276,545,560´¶³qªÑ©ÎTranche预¥ý资§Uªº认ªÑ权证¡A¥i¦æ¨Ï11,061,822 ADS¡C²Ä¤@§å认ªÑ权证¥]¬A¡]i¡^50¢Hªº认ªÑ权证¡A¦b发¦æ¦Z¤Î¤½¥¬§Ú们TREK-AD²Ä2b´Á临§É试验调¬datopic dermatitis¤¤eblasakimab¤½§i¤§¤é°_60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ®æ为¨CADS 6.50¬ü¤¸¡A¥H¤Î¡]ii¡^50¢Hªº认ªÑ权证¡A¥u¯à¦beblasakimab¤½§i¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ®æ°ò¤_ADSªº¥[权¥§¡É²®æ¡]VWAP¡^¡A该ɲ®æ¦beblasakimab¤½§i¦Zªº¯S©w´Á间内测¶q¡C²Ä¤G§å认ªÑ权证¦Pý©¥]¬A¡]i¡^50¢Hªº认ªÑ权证¡A¦b发¦æ¦Z¤Î¤½¥¬§Ú们计¦E进¦æªº²Ä2阶¬q·§©À验证试验调¬dfarudodstat时发¥¬¦Ü60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ®æ为¨CADS 8.15¬ü¤¸¡C Relationships with Selling Shareholders Except as otherwise disclosed in the footnotes to the table above and as described below, none of the selling shareholders has, or within the past threeyears has had, any position, office or other material relationship with us. On February 24, 2023, we entered into the Unit Purchase Agreement with the selling shareholders, or the Purchasers, pursuant to which we agreed tosell to the Purchasers, in the Private Placement, an aggregate of (i) 59,957,865 ordinary shares (or the equivalent of 2,398,314 ADSs) and (ii)52,401,685 ordinary shares issuable upon the exercise of Pre-Funded Warrants (or the equivalent of 2,096,067 ADSs), at a purchase price of $0.178 perordinary share (or the equivalent of $4.45 per ADS) and $4.4475 per Pre-Funded Warrant. The Private Placement closed on February 27, 2023. As part of the Private Placement, the Purchasers also received two tranches of Warrants exercisable in the aggregate for up to 276,545,560 ordinaryshares or Tranche Pre-Funded Warrants exercisable for 11,061,822 ADSs. The first tranche of Warrants is comprised (i) 50% of Warrants that areexercisable upon issuance and until 60 days after the public announcement of our topline data from our TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis, or the eblasakimab announcement, at an exercise price of $6.50 per ADS, and (ii) 50% of warrants which can only beexercised within 60 days after the eblasakimab announcement at an exercise price based on the higher of $6.50 and a 50% discount to the ADSs¡¦ volume-weighted average price, or VWAP, measured across a specified period after the eblasakimab announcement. The second tranche of Warrants issimilarly comprised (i) 50% of Warrants that are exercisable upon issuance until 60 days after the public announcement of topline interim data from ourplanned Phase 2 proof of concept trial investigating farudodstat , or the farudodstat announcement, at an exercise price of $8.15 pe
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/26 ¤W¤È 08:41:39
²Ä 6074 ½g¦^À³
|
¥»¦¸¶Ò¸ê¤@»õ¬ü¤¸¡B¥Î388,905,110ì©lªÑ¡D ADR(1¡G25)= 388,905,110/25=15,556,204ªÑADR ¥§¡¨CªÑ6.42¬ü¤¸. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/26 ¤W¤È 07:07:38
²Ä 6073 ½g¦^À³
|
¥»¦¸»{Áʪº4¤j¤½¥q»{ÁÊ(§t»{ÁÊÅvÃÒ)ì©lªÑ¼Æ//¨p¶Ò«e«ùªÑ//¥¼¨Ó«ùªÑ¦Xp
1.BVF 272¡B233¡B565 2.TANG 38,890,515//(¨p¶Ò«eì«ùªÑ26,824,625)¡B¥¼¨Ó«ùªÑ¦Xp65,715,140 3.K2¡C 38,890,515//(¨p¶Ò«eì«ùªÑ1,402,891) 4.Florian38,890,515//(¨p¶Ò«eì«ùªÑ9,131,810) ¦Xp 388,905,110//
ir.aslanpharma.com/static-files/8ef0bdc0-36a2-45f0-9424-fe9c5722521d P.10
Name of Selling Shareholder Shares Beneficially Owned Prior to Offering(1)
Number of Shares Being Offered
SharesBeneficiallyOwnedAfterOffering(2) Number Percent Number Percent 1.Entities affiliated with BVF Partners L.P. (3) 42,445,150 9.99% 272,233,565 ¡X ¡X 2.Tang Capital Partners, LP(4) 41,134,322 9.99% 38,890,515 26,824,625 6.56% 3.K2 HealthVentures Equity Trust LLC(5) 26,466,126 6.24% 38,890,515 1,402,891 *
4.Florian Schönharting(6) 20,394,529 4.99% 38,890,515 9,131,810 2.23% * Represents benefi |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/25 ¤U¤È 03:31:05
²Ä 6072 ½g¦^À³
|
7¤ëªì¤½§iªºASLSN004 2b¸Ñª¼¼Æ¾Ú ¥«È¼ÒÀÀ¡G Y ¤@¡BIGA0,1>54%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù31.25¬ü¤¸¡D ¶Ò资»ù25¬ü¤¸ ¥«È25¬ü¤¸x4¸U¤dªÑ=10»õ¬ü¤¸
¤G¡BIGA0,1=45%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù15¬ü¤¸¡D¶Ò资»ù12¬ü¤¸ ¥«È4.8»õ¬ü¤¸¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/25 ¤U¤È 03:13:56
²Ä 6071 ½g¦^À³
|
3¬ü¤¸º¦¨ì30¬ü¤¸ªº¼ç¤O⋯7¤ë
¦b6550¥_·¥¬P¬Ý¹L¡A10¤¸/ªÑ¨p¶Ò30»õ¥x¹ô¡Aº¦¨ì100¤¸/ªÑ¡C2021/¤¸¤ë¡ã2022/02 µM«á¤T´Á¸Ñª¼¦¨¥\º¦¨ì232¡]2022/09¡^¡A¥Ø«e¦^¨ì96¤¸¡C
·|µu缐¾Þ§@ªÌ¡A¤£·|©ñ±¼¦¹10¿Â½º¦ªº¾÷·|ªº¡C
Tang ¸ê¥»¤½¥q¡A§t»{ªÑÅvÃÒ¡A¦@¥[½X¨ì5¸U¤dªÑì©lªÑ¡A¥Ø«eADR¡]1:25¡^¬ù2000¤dªÑ¡C¡]²Ä¤G¤jªÑªF¡^¡A12¤ë©³«ùªÑ1072¤dªÑADR¡]1:25¡^
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/3/25 ¤U¤È 02:46:47
²Ä 6070 ½g¦^À³
|
´«ºâ¦^´¶³qªÑ¥u¦³2.91/25*30=·s¥x¹ô3.49/ªÑ¡A¹ï«Ü¦h¦Ñ·à¤ÍÁÙ¬O«Ü¨¯Wªº»ù®æ¡F§Y¨ÏADRº¦¨ì25¶ô¤]¬O¥x¹ô30¶ô¡AÁÙ¬O¦Ñ¸Ü¤@¥y¡A§Æ±æ¦Ñ·à¤Í̳£¯à¸Ñ®M~~~~~~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/25 ¤W¤È 10:10:18
²Ä 6069 ½g¦^À³
|
2022¦~¡B²Ä4©u°]³ø 2022/12/31 ²{ª÷¡G56.9¦Ê¸U¬ü¤¸ ²bÈ¡G8¦Ê36¸U¬ü¤¸ 2022¦~5100¸U¬ü¤¸¤§损¥¢(¥Dn¬ãµo¶O¥Î3600¸U¬ü¤¸¡D¥§¡¨C©u1400¸U¬ü¤¸¥ª¥k¡B ¡K¡K¥H¤W¬°¨p¶Ò¥D¦]¤§¤@
Cash and cash equivalents total $56.9 million as of December 31, 2022 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/25 ¤W¤È 09:55:25
²Ä 6068 ½g¦^À³
|
¥Ø«e¸ê¥»ÃBADR¡B4¸U¤dªÑ(ADR:1:25) ¦©°£¤wµo¦æ¡B¤º³¡¿EÀy¤Îk2»{ªÑ¡B ©Ò³Ñ¬ù8000¤dªÑADR¥i¥«³õ¾P°â©Î¥]¾P¡K ³Ì°ª¶Ò2»õ¬ü¤¸¡B¥Ø¼Ð¶Ò¸ê»ù25¬ü¤¸/ADR
±À¦ô25/80%=30¬ü¤¸¤@¤@³Ì°ª¤½¥q»{¬°¥i¯àªº¥Ø¼Ð»ù¡D
2/24¨p¶Ò0.89*5=4.45¬ü¤¸(2000¸U¬ü¤¸) 2/24»{ªÑÅv(1.3-1.603)x5=6.5-9.15 (¶Ò8000¸U¬ü¤¸,7¤ë¸Ñª¼«á60¤Ñ¤º»{ÁÊ¡D
Tang资¥»¤½¥q2¤ë24¤é¥ç¦³»{¨p¶Ò¡D ¬°²Ä¤G¤j«ùªÑ(2¤ë28¤é)¡B¦Xp«ùªÑ¬ù4.1¸U¤dªÑì©lªÑ¡B©MBVF¶°¹Î¬Û·í¬Ò¬°9.99%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/25 ¤W¤È 09:13:19
²Ä 6067 ½g¦^À³
|
1.³Ì°ª2»õ¬ü¤¸ªº¶Ò¸êp¹º(2023/03/24´£¥X) ir.aslanpharma.com/static-files/0f9bf9a7-f0e1-4b22-9f67-4bbfa0a5dae8
SUBJECT TO COMPLETION, DATED MARCH 24, 2023 PROSPECTUS $200,000,000(2»õ¬ü¤¸ªº¶Ò¸êp¹º) Ordinary Shares American Depositary Shares representing Ordinary Shares
¤£¥]¬A¤§«e(2¤ë24¤é)³Ì°ª¨p¶Ò1»õ¬ü¤¸.
¥¼p¥t¥~¤º³¡¿EÀy¤Îk2¨p¶Òp2000¸U¬ü¤¸,¬ù50,000,000ì©lªÑ. ¤º³¡¿EÀy¶}©l»{ªÑ: ir.aslanpharma.com/static-files/80855ba6-3677-446a-ae3d-d4c0d9efb657
¦Xp¥i¶Ò¸êª÷3.2»õ¬ü¤¸.
2.¦~³ø ir.aslanpharma.com/static-files/44f85422-f9c7-43ba-83cb-5cba2b68d8cb
2¤ë28¤é¤î, «ùªÑ¶W¹L5%ªÑªF¦³4¦ì.----p.106 ¤½¥q¤º³¡«ùªÑ5.26%(22,399,939ì©lªÑ)
¥H¤W¨Ì2023¦~2¤ë28¤é¤wµo¦æ408,681,230 ì©lªÑ.
3.²Öp¦Ü3¤ë20¤é¤wµo¦æ737,628,475ì©lªÑ
ir.aslanpharma.com/static-files/8ef0bdc0-36a2-45f0-9424-fe9c5722521d p.8 Equity: Ordinary shares, $0.01 par value per share, 500,000,000 shares authorized, 348,723,365 shares issued and outstanding, actual; and 737,628,475
The number of ordinary shares outstanding in the table above is based on 348,723,365 ordinary shares outstanding as of December 31, 2022 on an actual basis and excludes: • 48,822,715 ordinary shares issuable upon the exercise of share options outstanding as of December 31, 2022 under our 2014 Employee Share Option Scheme Plan, our 2017 Employee Share Option Plan and our 2020 Equity Incentive Plan, at a weighted average exercise price of $0.26 per ordinary share; and • 1,402,891 ordinary shares issuable upon the exercise of an outstanding warrant issued in July 2021 to K2 HealthVentures Equity Trust LLC, at an exercise price of $0.5257 per ordinary share, pursuant to that certain Loan, Guaranty, and Security Agreement with K2 HealthVentures LLC in connection with the drawdown of our loan facilities. In addition, as of the date of this prospectus, 53,393,470 ordinary shares (representing 2,135,738 ADSs) have been issued to JPMorgan Chase Bank, N.A., as depositary, which are being held for future sales and issuances of ADSs, if any, under that certain Open Market Sale AgreementSM that we entered into with Jefferies LLC on October 9, 2020, as amended from time to time. ¤Wªí¤¤µo¦æ¦b¥~ªº´¶³qªÑ¼Æ¶q¬O®Ú¾ÚºI¦Ü2022¦~12¤ë31¤éµo¦æ¦b¥~´¶³qªÑ348,723,365ªÑ¹ê»Ú °ò¦¨Ã±Æ°£¡G • ºI¦Ü 2022 ¦~ 12 ¤ë 31 ¤é¡A®Ú¾Ú§Ú̪º 2014 ¦~¥¼¦æ¨ÏÁʪÑÅv¡A¥iµo¦æ 48,822,715 ªÑ´¶³qªÑ û¤uªÑ²¼´ÁÅvp¹º¡B§Ú̪º 2017 ¦~û¤uªÑ²¼´ÁÅvp¹º©M§Ú̪º 2020 ¦~ªÑÅv¿EÀyp¹º¡A«ö¥[Åv ¥§¡¦æ¨Ï»ù¬°¨CªÑ´¶³qªÑ 0.26 ¬ü¤¸¡F ©M • 1,402,891 ªÑ´¶³qªÑ¥i¦b 2021 ¦~ 7 ¤ë¦V K2 HealthVentures Equity Trust µo¦æªº¥¼¦æ¨Ï»{ªÑÅvÃÒ¦æ¨Ï«áµo¦æ LLC¡A®Ú¾Ú»P K2 ñqªº¯S©w¶U´Ú¡B¾á«O©M¾á«O¨óij¡A¦æ¨Ï»ù¬°¨CªÑ´¶³qªÑ 0.5257 ¬ü¤¸ HealthVentures LLC ³B²z§Ú̶U´ÚÃB«×ªº´£¨ú¡C ¦¹¥~¡AºI¦Ü¥»©ÛªÑ»¡©ú®Ñµo¥¬¤§¤é¡A¤w¦V¼¯®Ú¤j³q»È¦æµo¦æ 53,393,470 ªÑ´¶³qªÑ¡]¬Û·í©ó 2,135,738 ªÑ¬ü°ê¦s°U¾ÌÃÒ¡^¡A N.A.¡A§@¬°«OºÞ¤H¡A®Ú¾Ú§Ú̽T©wªº¬Y¨Ç¤½¶}¥«³õ¾P°â¨óijSM¡A¬°¥¼¨Ó¾P°â©Mµo¦æ ADS¡]¦pªG¦³¡^¦Ó«ù¦³ ©ó 2020 ¦~ 10 ¤ë 9 ¤é»P Jefferies LLC ñq¡A¨Ã¸g¤£®É×q¡C shares issued and outstanding as adjusted |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/23 ¤W¤È 10:09:49
²Ä 6066 ½g¦^À³
|
ASLAN004 2B AD ³Ì·s²§°Ê:
°±¤î¦¬®×,¹ê»Ú¦¬®×302¤H,6¤ë30§¹¦¨¥Dn(16¶g)Á{§É.
clinicaltrials.gov/ct2/show/NCT05158023 Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
Study Type : Interventional (Clinical Trial) Actual Enrollment : 302 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis Actual Study Start Date : March 16, 2022 Estimated Primary Completion Date : June 30, 2023 Estimated Study Completion Date : September 30, 2023
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/16 ¤W¤È 08:54:17
²Ä 6065 ½g¦^À³
|
¬Ý¹L65/83(78%)¥¼¸Ñª¼ªºBVF¤½¥q¡B¤w¤j¶q¶R2000¸U¬ü¤¸¡D(0.89*5=4.45³æ»ù/ADR¡B1¡G25) ¸Ñª¼«eªº¦æ±¡³Ì°ª15-22.25,¨é°Ó¥Ø¼Ð»ù
¤£¨ì4Ó¤ë¡B¦³¦p¦¹Ãz§Qªº¼Ðªº¡D ¥@¬É¨ºùاä?
¸Ñª¼«e½æ¤@½ëµu½uÀò§Q¥i¯à¼Æ¿?¡D ¬Ý¬ÝCNTB 2021¦~7¤ë15¤é2b AD¸Ñª¼«eªº¦æ±¡¡D15¬ü¤¸º¦¨ì26¬ü¤¸¡D (2021/11¤ë¡B¤½§G¸Ñª¼¼Æ¾Ú)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/3/15 ¤U¤È 11:18:14
²Ä 6064 ½g¦^À³
|
¬üªÑ«®À4¡B500ÂI¡A Asln¤@ªK¿W¨q¡A¦bº¦¤°»ò¡H
ªÑ²¼¥«³õ¸¹ºÙ³Ì¦³®Ä²vªº¥«³õ¡A ©Ò¥H©O¡H
Ä~Äò¬ÝÀ¸¡ã
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/15 ¤U¤È 11:06:49
²Ä 6063 ½g¦^À³
|
¤j®a¦¨¥»¦U¦³¤£¦P¡A¥§¡¸¨¦b5~7¬ü¤¸¤§¶¡³Ì¦h¡A²{¦b«ùªÑ¥u³Ñ¤¤À¤§¤@¡A25¬ü¤¸¥H¤W½æÀ£¤~·|¤ñ¸û«¡A ¥H¤W¬OÓ¤H±À´ú¡A¶È¨Ñ°Ñ¦Ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/3/15 ¤U¤È 10:41:23
²Ä 6062 ½g¦^À³
|
¥xªÑ¤U¥««e4¤dªÑ ÅÜADR/5=800 ³o¦¸´î¸ê/5=160ªÑ ¨ºnº¦¨ì10¦h¶ô¤~¯à¦^¥»QQ ºGµ´¤H¾Èªü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/15 ¤U¤È 01:43:48
²Ä 6061 ½g¦^À³
|
111¦~8¤ë23¤é¤½§i¦¨¥ß65³Bªº¦¬®×¤¤¤ß¡B 112¦~1¤ë30¤é¦A·s¼W18³B¦¬®×¤¤¤ß(¬Ò¦ì¦bªiÄõ)¡A¦@83³B¡B¤µ¦~2¤ë24¤é¤½§i³Ì«á¤@¦ì¤w©Û¶Ò¡C
8¤ë23¤éªº65³B¦¬®×¤¤¤ß+2Ӥ몺¦¬ªv+16¶g¸ÕÅç+1Ó¤ë¼Æ¾Ú¾ã²z=112¦~3¤ë23¤é (°ò¥»¤W«DªiÄõªº¦¬®×¤¤¤ß³£¤wµ²®×) 8¤ë23¤éªº65³B¦¬®×¤¤¤ß¼Æ¾Ú°÷¤µ¦~5¤ë¦bªF¨Ê°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ijµoªí¤F¡C (¨È·à±dª½±µ¬D³ÌÃøªºµoªí¡G±´°Q eblasakimab ¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/15 ¤W¤È 10:14:26
²Ä 6060 ½g¦^À³
|
clinicaltrials.gov/ct2/history/NCT05158023?A=12&B=13&C=merged#StudyPageTop ¤¸¤ë30¤é ·s¼W18³B©Û¶ÒÂI,¦@83³B, ¤G¤ë24¤é¤½§i³Ì«á¤@¦ì¤w©Û¶Ò.
16¶gªvÀø.
³Ì§Ö6¤ë16¤é¥i¸Ñª¼. ¥Ø«e¤w§¹¦¨16¶gªvÀøªº¥i¯àªñ65/83=78%.
Ó¤H²q¤½¥q¥i¯à¬O6¤ë¤¤¤U¦¯¥ý¸Ñª¼,¥ý¥h½Í¥]¾P»ù«á,7¤ëªì¬ü°ê°ê¼y°²´Á«á¤½§G¼Æ¾Ú. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/15 ¤W¤È 09:57:45
²Ä 6059 ½g¦^À³
|
¦A¸É¥R¡G 5¤ë¦³¥i¯à¬O7¤ë¸Ñª¼«eªº³Ì«á¤@¦¸°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¡C 쥻¤µ¦~4¤ë¨È·à±d¬On004¸Ñª¼ªº¡C ¤]´N¬O004ªº9¦¨Àø®Ä4¤ë¥÷´Nª¾¹D¤F¡C¨È·à±d¥u¬O§âì©w4¤ënµoªíªº¼Æ¾Ú¡A´«Ó¼Ò¦¡©ó5¤ëªF¨Ê°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij´¦ÅS¦Ó¤w¡C
ºî¾ã¡G004ªº¼Æ¾Ú¬O¥¿¦Vªº¡C¥u¬O¤£¾å±oÀø®ÄĹ¹L§ùÁת¢¦h¤Ö¦Ó¤w¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/15 ¤W¤È 09:15:02
²Ä 6058 ½g¦^À³
|
³o¦¸5¤ë¦bªF¨Ê¡A¨È·à±dµoªíªº¬O±´°Q eblasakimab ¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¡A¥H¤Î¡K¡K¡K¡C
(ÅÞ¿è«ä¦Ò)¤]´N¬O»¡¡G 1.«DÃøªv³¡¦ì(Âß·F¡B¥|ªÏ)©Ò®i²{ªºÁ{§ÉÀø®Ä¬O¥¿¦Vªº¡C 2.¬JµM³o¦¸¬O±´°Q¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¡A´«¥y¸Ü»¡¡A´N¬O³sÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¤]¬O¥¿¦Vªº¡C(¤£µM´N¤£¥Î®³¥X¨Ó±´°Q¤F)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/14 ¤U¤È 07:18:37
²Ä 6057 ½g¦^À³
|
2023-03-14 ASLAN Pharmaceuticals «Å§G¦b²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¤W±µ¨ü¨â¥÷ºKn¶i¦æ®ü³ø®i¥Ü ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 3 ¤ë 14 ¤é¡]Àô²y·s»DªÀ¡^¡X¡X ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¨â®a¤½¥q ¦b 2023 ¦~ 5 ¤ë 10 ¤é¦Ü 13 ¤é¦b¤é¥»ªF¨ÊÁ|¦æªº²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¤W¡AÃö©ó eblasakimab ªººKn¤w³Q±µ¨ü¥Î©ó®ü³ø®i¥Ü¡C ·|ij¤W®i¥Üªº®ü³ø±´°Q¤F eblasakimab ¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¡A¥H¤Î¥¦¦b¯SÀ³©Ê¥Öª¢¤¤³q¹L¦hºØ¤À¤l³~®|´î»´¼ç¦bæ±Äo©M¶W±Ó·Pı¯«¸gÅÖºûªº¼ç¤O¡C
²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij®ü³ø¸Ô±¡
®ü³ø 1¡G¦b 1 ´Á¬ã¨s¤¤¡AEblasakimab ³æ¤@Àøªk¥i§ïµ½¾ãÓ¸Ñå°Ï°ìªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¯gª¬ ¡]ºKn½s¸¹¡G657¡^
®ü³ø 2¡G³q¹L¨Ï¥Î eblasakimab ¹v¦V IL-13R£\1 ¨ÓªýÂ_°£æ±Äo¤§¥~ªº¯«¸g½Õ¸` ¡]ºKn½s¸¹¡G1594¡^
®ü³ø¥i¥Î¤é´Á¡G2023 ¦~ 5 ¤ë 10 ¤é
®ü³ø±N¦bºt¥Ü«á¦b¨È·à±dºô¯¸ªº§ë¸êªÌÃö«Y³¡¤À¦b½u¬d¬Ý¡C¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/14 ¤U¤È 06:04:31
²Ä 6056 ½g¦^À³
|
¤Ñ©R¤j
¸Ø±i¤j»¡ªº´Á¤¤³ø§i¡A¤£¬O«ü¥¿¦¡ªº¸Ñª¼³ø§i¡A
¬O«üBVF¤@©w¦³¬Ý¨ì2b¬ÛÃö¸ÕÅç¼Æ¾Ú¡A
¸g¸Ó¤½¥q¬ã§P¦³¦¨¥\¾÷·|¡A¤~·|°µ¦¹¨M
©w¡A¥ý§ë¸ê2000¸U¬üª÷¡A2b¦¨¥\«á¦A§ë¤J8000¸U¬üª÷¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/14 ¤U¤È 05:32:54
²Ä 6055 ½g¦^À³
|
¸Ø±i¤j¡A BVF ¬Ý¨ìªº¬O¥¼¸Ñª¼ªº¦U¶µ«ü¼Ð¡A¬Ò¬O¥§¡¼Æ¡C
ASLAN ·|´£¨Ñ¤À§é¡ABvF¤]·|§ä±M®a¤À§é¡C
¨S¦³´Á¤¤¸Ñª¼³ø§iªº¦s¦b¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/14 ¤U¤È 05:09:46
²Ä 6054 ½g¦^À³
|
BVF Partners L.P. (Biotechnology Value Fund) is a Hedge Fund Manager located in San Francisco, CA United States, North America, and was founded in 1993. , SWFI has 2 personal contacts available for CSV Export. BVF Partners L.P.¤]¬O¤@®a¹ï¨R(¥Í§Þ)°òª÷¡A¦Ó¥¦¬O¯¸¦b¨È·à±d³oÃ䪺¡ABVF Partners L.P.À³¸Ó¬Ý¹L¨È·à±d004ªº´Á¤¤³ø§i«á¤~É¥X¥x¹ô6»õ¤¸¡C²{¦bBVF Partners L.P.¦b¸ò¨ä¥L¹ï¨R°òª÷¹ï½ä¡C 7¤ë¥÷´Nª¾¹Dµ²ªG¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/14 ¤U¤È 12:01:04
²Ä 6053 ½g¦^À³
|
¨ÌIGA0,1=44% ©Î54% ¦Ó©w, Y54%¥i¬°44%°ª¤@¿¥Ø¼Ð»ù.
¨Ì¾Ú¥D¤Oú³°ÓPiper Sandler¥Ø¼Ð»ù3*5¬ü¤¸ADR(1:25).
¥]¾P»ù=3*80%*5=12¬ü¤¸ADR(1:25).-------IGA0,1=44%,¥«È4.8»õ¬ü¤¸ ¥]¾P»ù=3*80%*2*5=24¬ü¤¸ADR(1:25).-------IGA0,1=54%,¥«È9.6»õ¬ü¤¸
¤@.°²³]:ASLAN004 2b ,IGA0,1=44%,©MLebrikizumab ¬Û·í, ¥«³õ=dupilumab 80»õ¬ü¤¸*46%(9/15°¾¦n½Õ¬d)*50%(©MLebrikizumab ¥¤À¥«³õ)=18.4»õ¤¸¦y峄¾P°â
**¤G½uAD=18.4*66%*70%(¦©°£«D¶Ç²ÎAD)=8.5»õ¬ü¤¸¦y峄¾P°â **¨ä¥L¾AÀ³¯g=18.4/.55*.45=15»õ¤¸¦y峄¾P°â--
AD§é²{26.9/20*11*95%(§é²{¦]¤l¦]¤É®§¦Ó¼W¥[)=14»õ¬ü¤¸ ¨ä¥L¾AÀ³¯g§é²{15/20*11*50%*95%=3.9»õ¬ü¤¸ ²{ª÷:3»õ¬ü¤¸ 003¥«È°²³]0.6*3=1.8»õ¬ü¤¸ ¥H¤W¦Xp=22.7»õ¬ü¤¸---³Q¨ÖÁÊ»ù
ªÑ»ùADR(1:25):22.7»õ¬ü¤¸/4¸U¤dªÑADR=57¬ü¤¸/ADR----³Q¨ÖÁÊ»ù
¤G.°²³]:ASLAN004 2b ,IGA0,1=54% ¥«³õ=dupilumab 80»õ¬ü¤¸*46%(9/15°¾¦n½Õ¬d)=36.8»õ¤¸¦y峄¾P°â
**¤G½uAD=36.8*66%*70%(¦©°£«D¶Ç²ÎAD)=17»õ¤¸¦y峄¾P°â) **¨ä¥L¾AÀ³¯g=36.8/.55*.45=30»õ¤¸¦y峄¾P°â--
§é²{53.8/20*11*95%(§é²{¦]¤l¦]¤É®§¦Ó¼W¥[)+30/20*11*50%*95% =28.1+7.8 =35.9»õ¬ü¤¸
²{ª÷:3»õ¬ü¤¸ 003¥«È°²³]0.6*3=1.8»õ¬ü¤¸ ¥H¤W¦Xp=40.7»õ¬ü¤¸---³Q¨ÖÁÊ»ù
ªÑ»ùADR(1:25):40.7»õ¬ü¤¸/4¸U¤dªÑADR=102¬ü¤¸/ADR----³Q¨ÖÁÊ»ù |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/14 ¤W¤È 11:13:38
²Ä 6052 ½g¦^À³
|
¤Ñ©R¤j¤j3¨Æ½Ð±Ð¡G 1.¨Ì±z¤âÃä¸ê®Æ¤Î¸gÅç¨Ó¬Ý ¨È·à±d004ªº¼Ú¬w±ÂÅvª÷¬ù²ö¬O¦h¤Ö»õ¬üª÷??? Ans¡G00»õ~00»õ¬üª÷
2.004¤T´Á©Ò»Ý¸êª÷¬ù²ö»Ý´X»õ¬üª÷ Ans¡G00»õ~00»õ¬üª÷ 3.¦©°£¼Ú¬w±ÂÅvª÷«á¡AY7¤ë ¨p¶Ò20,000¥aªÑ¡A¦X²zªÑ»ù°Ï¶¡??? Ans¡G00~00¬ü¤¸/ADR ·PÁ±z
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/14 ¤W¤È 10:49:52
²Ä 6051 ½g¦^À³
|
Lebrikizumab 2b IGA0,1Àø®Ä
1.125mgxQ4W=26.6% 2.250mgxQ4W=33.7% 3.250mgxQ2W=44.6% 4.¹ï·Ó组=15.3% ¦©°£¹ï·Ó组«e¤T组¥§¡34.9%
¥¼¸Ñª¼«e¤ñDupilumab 3´Á38%/36%®t¡D
Lebrikizumabªº¤½¥qDERM¸Ñª¼«eªÑ»ù§e³Ì§C¬ù5¶ô¦h¬ü¤¸¡D ¸Ñª¼«á¥]¾P»ù13.25¬ü¤¸ ³Q¨ÖÁÊ»ù18.75¬ü¤¸(11»õ¬ü¤¸)
ASLAN004 2b ¨Ñ¥|组¹êÅç组¤Î¤@组¹ï·Ó组¡D
Ó¤H¤ÀªRIGA0,1¡B³Ì°ª¾÷²v¡D¦p¤U¡G 1.¹ï·Ó组IGA0,1=15%¥ª¥k 2.Q4Wx400mg 27% 3.Q4WX600mg¬ù33%(ªñLebr.)
3.Q2Wx400mg¬ù45%~54% Q2Wx300mg¬ù38%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/3/14 ¤W¤È 10:26:30
²Ä 6050 ½g¦^À³
|
§Ú¤]§Æ±æBVFÀ£ª`¬O¹ïªº¡A¯¬ºÖ¤j®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/14 ¤W¤È 09:44:00
²Ä 6049 ½g¦^À³
|
BVF ªá2000¸U¬ü¤¸(6»õ¥x¹ô)¡B«÷2b¸Ñª¼¦¨¥\¡B 预©w»{ªÑÅv³Ì°ª8000¸U¬ü¤¸(24»õ¥x¹ô)
±M·~¥Í§Þ§ë资°òª÷¡B¦p¦¹¤Uª`¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/3/14 ¤W¤È 09:30:12
²Ä 6048 ½g¦^À³
|
Àò§Q´î¸ê¸òÁ«·l´î¸ê®t«Ü¦h¦n¶Ü? µ´¤j³¡¤ÀªºÁ«·l´î¸ê´î¨ì³Ì«á³£¬OªÑ¼ÆÅܫܤ֪ѻù¤]ÅܫܧC Á`¤§...ÁöµM§Ú¨S½æ¡A¦ý¹ï¨È·à±d´XµL´Á«Ý §Ú¦Û¤v¤w·í§@³oµ§¿ú¨S¤F¡A¤C¤ë¦A¨Ó¬Ý¬ÝªÑ»ùÅÜ«ç¼Ë ¤j®aÀ³¸Ó¤]n¦³³o¼Ëªº»{ª¾ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/13 ¤U¤È 11:17:26
²Ä 6047 ½g¦^À³
|
¦ÑÁªº´î¸ê«Øij°ê¥¨¸³®yÅ¥¶i¥h¤F¡A ¦b·~ÁZ¦nªº®ÉÔ¨CªÑÀò§Q·|¦]¬°ªÑ¥»´î¤Ö¦Ó¼W¥[¡A´¿³y´N¤d¤¸ªÑ»ù¡A¥i¥H ·j´M¥H¤U¼ÐÃD¡A¾é¸Ñì¥Ñ
°ê¥¨²Ä5¦¸´î¸ê¡n¹L¥h4¦¸½G¨ ±qÂû³J¤ô»åÅܤdª÷ªÑ ´î¸ê¬OªÑ»ù¸UÆF¤¦¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2023/3/13 ¤U¤È 10:50:13
²Ä 6046 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/13 ¤U¤È 10:27:36
²Ä 6045 ½g¦^À³
|
ASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^ªñ´Á¦^¸¨ 25% ¼W¥[¤@¦~Á«·l¡A¹ï¨R°òª÷©Ò¦³ªÌ¥i¯à±Ä¨úÄY¼F±¹¬I
«n¨£¸Ñ Ų©ó¾÷ºc«ù¦³¤j¶qªÑ²¼¡A¨È·à±dªºªÑ»ù¥i¯à·|¨ü¨ì¨ä¥æ©ö¨M©wªº¼vÅT
BVF Partners L.P. ¾Ö¦³¤½¥q 63% ªºªÑ¥÷
±N¤½¥q¹L¥h·~ÁZªº¼Æ¾Ú»P©Ò¦³Åv¬ã¨s¤@°_¨Ï¥Î¡A¥i¥H§ó¦n¦aµû¦ô¤½¥q¥¼¨Óªº·~ÁZ
ASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^ªº¨C¤@¦ì§ë¸êªÌ³£À³¸Ó¤F¸Ñ³Ì±j¤jªºªÑªF¸sÅé¡C ¹ï¨R°òª÷¾Ö¦³70%ªºªÑ¥÷¡A¾Ö¦³¸Ó¤½¥qªº³Ì¤jªÑ¥÷¡C ´«¥y¸Ü»¡¡A¸Ó¶°¹Î±N±q¥L̹綠¥qªº§ë¸ê¤¤Àò±o³Ì¦h¡]©Î·l¥¢³Ì¦h¡^¡C
¤W¶g¡A¹ï¨R°òª÷§ë¸êªÌªº«ùªÑ»ùȤU°¤F 25%¡C ³Ìªñªº·l¥¢¥[¤WªÑªF 29% ªº¤@¦~·l¥¢¡A¥i¯à¤£·|Åý³o¸s§ë¸êªÌº¡·N¡C ¹ï¨R°òª÷³q±`±Ä¥Î¿E¶iªººÞ²z¤è¦¡¡A³q±`¥HÃöª`µu´Á§Q¼í¬°¥Ø¼Ð¡C Ų©ó¥L̦b ASLAN Pharmaceuticals ªº°ª«ùªÑ¶q¡A¥L֦̾³¥¨¤jªºÅv¤O¡A¨Ã¥B«ùÄòªí²{¤£¨Î¥i¯à¾ÉP¥L̼vÅTºÞ²z¨Mµ¦¡A¦Ó³o¨Ç¨Mµ¦¥i¯à¤£·|µû¦ô¤½¥qªºªø´Á«e´º¡C
Åý§ÚÌ¥J²Ó¬Ý¬Ý¤£¦PÃþ«¬ªºªÑªF¥i¥H§i¶D§Ú̦³Ãö¨È·à±d»sÃĪºþ¨Ç«H®§¡C
¬d¬Ý§Ú̹ï¨È·à±d»sÃĪº³Ì·s¤ÀªR
©Ò¦³Åv¤À¸Ñ ¾÷ºc©Ò¦³Åv§i¶D§ÚÌÃö©ó¨È·à±d»sÃĪº¤°»ò«H®§¡H ¾÷ºc§ë¸êªÌ³q±`±N¦Û¤vªº¦^³ø»P´¶¹MÃöª`ªº«ü¼Æªº¦^³ø¶i¦æ¤ñ¸û¡C ¦]¦¹¡A¥L̳q±`·|¦Ò¼{ÁʶR¬ÛÃö°ò·Ç«ü¼Æ¤¤¥]§tªº¸û¤j¤½¥q¡C
ASLAN Pharmaceuticals ¤w¸g¦bªÑ¥÷µn°O³B¾Ö¦³¾÷ºc¡C ¨Æ¹ê¤W¡A¥L̦b¤½¥q¾Ö¦³¥iÆ[ªºªÑ¥÷¡C ³o·N¨ýµÛ¬°³o¨Ç¾÷ºc¤u§@ªº¤ÀªR®v¤w¸g¬Ý¹L³o°¦ªÑ²¼¨Ã¥B¥L̳ßÅw¥¦¡C ¦ý´N¹³¨ä¥L¤H¤@¼Ë¡A¥LÌ¥i¯à¬O¿ùªº¡C ·í¦hÓ¾÷ºc¾Ö¦³¤@°¦ªÑ²¼®É¡A¥¦ÌÁ`¬O¦s¦b³B©ó¡§¾ÖÀ½¥æ©ö¡¨¤¤ªº·ÀI¡C ·í³o¼Ëªº¥æ©ö¥X²{°ÝÃD®É¡A¦h¤è¥i¯à·|Äv¬Û§Ö³t¥X°âªÑ²¼¡C ¦b¨S¦³¼Wªø¾ú¥vªº¤½¥q¤¤¡A³oºØ·ÀI§ó°ª¡C ±z¥i¥H¦b¤U¤è¬d¬Ý ASLAN Pharmaceuticals ªº¾ú¥v¦¬¯q©M¦¬¤J¡A¦ý½Ð°O¦í¡A¬G¨ÆÁ`¬O¦³§ó¦h¤º®e¡C
¦¬¯q©M¦¬¤J¼Wªø §Ú̪º¼Æ¾Úªí©ú¡A¹ï¨R°òª÷¾Ö¦³ ASLAN Pharmaceuticals 70% ªºªÑ¥÷¡C ³o¤Þ°_¤F§Úªºª`·N¡A¦]¬°¹ï¨R°òª÷¦³®É·|¸Õ¹Ï¼vÅTºÞ²z¼h¡A©Î±a¨Ó·|¬°ªÑªF³Ð³yªñ´Á»ùȪºÅܤơC ¤½¥q²Ä¤@¤jªÑªF¬°BVF Partners L.P.¡A«ùªÑ63%¡C ³o¹ê½è¤W·N¨ýµÛ¥L̹綠¥qªº¥¼¨Ó¦³¼sªxªº¼vÅT¡A¦pªG¤£¬O§¹¥þ±±¨îªº¸Ü¡C ´NI´º¦Ó¨¥¡A²Ä¤G¤jªÑªF«ù¦³¬ù 6.7% ªº¤wµo¦æªÑ¥÷¡A¨ä¦¸¬O²Ä¤T¤jªÑªF«ù¦³ 3.5% ªºªÑ¥÷¡C ¦¹¥~¡Aº®u°õ¦æ©x Carl Alan Jason Firth ¾Ö¦³¤½¥q 0.9% ªºªÑ¥÷¡C
ÁöµM¬ã¨s¤@®a¤½¥qªº¾÷ºc©Ò¦³Åv¼Æ¾Ú«Ü¦³·N¸q¡A¦ý¬ã¨s¤ÀªR®vªº±¡ºü¥H¤F¸Ñ·¦V¤]«Ü¦³·N¸q¡C ÁöµM¦³¤@¨Ç¤ÀªR®v³ø¾É¡A¦ý¸Ó¤½¥q¥i¯à¨Ã¥¼³Q¼sªx³ø¾É¡C ¦]¦¹¡A¥¦¥i¥H¦b¥¼¨ÓÀò±o§ó¦hÃöª`¡C
¨È·à±d»sÃĪº¤º³¡«ùªÑ ¤º³¡¤Hªº©w¸q¦b¤£¦P°ê®a¥i¯à²¤¦³¤£¦P¡A¦ý¸³¨Æ·|¦¨ûÁ`¬O«nªº¡C ¤½¥qºÞ²z¼h¹ï¸³¨Æ·|t³d¡A«áªÌÀ³¥NªíªÑªFªº§Q¯q¡C ȱoª`·Nªº¬O¡A¦³®É°ª¼hºÞ²z¤Hû¦Û¤v¤]¬O¸³¨Æ·|¦¨û¡C
¤j¦h¼Æ¤H»{¬°¤º³¡¤H«ùªÑ¬O¿n·¥ªº¡A¦]¬°¥¦¥i¥Hªí©ú¸³¨Æ·|»P¨ä¥LªÑªF«O«ù¤@P¡C µM¦Ó¡A¦b¬Y¨Ç±¡ªp¤U¡A¹L¦hªºÅv¤O¶°¤¤¦b³oÓ¸sÅ餤¡C
§Ú̷̳sªº¼Æ¾ÚÅã¥Ü¡A¤º³¡¤H¤h«ù¦³¨È·à±d»sÃĦ³¤½¥qªº³¡¤ÀªÑ¥÷¡C ¤º³¡¤H¤h¥H¥L̦ۤvªº¦W¸q«ù¦³³o®a»ùÈ 2.29 »õ¬ü¤¸ªº¤½¥q»ùÈ 290 ¸U¬ü¤¸ªºªÑ²¼¡C «Ü°ª¿³¬Ý¨ì¤º³¡¤H¤h¶i¦æ¤@¨Ç§ë¸ê¡A¦ý¥i¯àȱoÀˬd¤@¤U³o¨Ç¤º³¡¤H¤h¬O§_¤@ª½¦bÁʶR¡C
¤@¯ë¤½¦³»s ¥]¬A´²¤á§ë¸êªÌ¦b¤ºªº¤½²³¾Ö¦³¸Ó¤½¥q 13% ªºªÑ¥÷¡A¦]¦¹¤£®e©¿µø¡C ÁöµM³oºØ³W¼Òªº©Ò¦³Åv¥i¯à¤£¨¬¥H¨Ï¬Fµ¦¨M©w¹ï¥L̦³§Q¡A¦ý¥L̤´µM¥i¥H¹ï¤½¥q¬Fµ¦²£¥Í¶°Åé¼vÅT¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/3/13 ¤U¤È 10:26:06
²Ä 6044 ½g¦^À³
|
¬JµM¨S¶]¡A´N¼ÖÆ[¤@ÂI§a¡I °®£|£¸£±¤]¬O¥u¯à¬Ý¦oªíºt¡A ¦ó¤£¯¬ºÖ¦Û¤v«e³~¥ú©ú🤩
§Ú¿@ÁY«áÁÙ¦³3¸U¦hªÑ¡A ¸é²î·d¤£¦n¤]¯àº¡¸ü¦ÓÂk¡I Á|ªM¡ã¯¬§ÚÌ⋯ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/13 ¤U¤È 10:23:23
²Ä 6043 ½g¦^À³
|
¤j®a¤£¥Î¤Ó´dÆ[¡A³Ì¤Ö½æÀ£´î¤Ö¦Ê¤À¤§¤K¤Q¡A½æÀ£¤Ö¸I¨ì¦n®ø®§·|³y¦¨°l»ùªºÁ`¶R¶i²{¶H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/3/13 ¤U¤È 09:55:53
²Ä 6042 ½g¦^À³
|
´N¬O¸é²î¨S¿ù...§Ú³Ñ4000ªÑ´N·íÃz±¼¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/13 ¤U¤È 04:43:25
²Ä 6041 ½g¦^À³
|
¬Ý¨ìªÑ¼ÆÅܦ¨7620ªÑ
¤ß²z«Ü·F¡A¤W¤F¸é²î¡Ä
¤@¯ë´î¸ê«á·|¦AÄò¶^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/13 ¤W¤È 10:15:30
²Ä 6040 ½g¦^À³
|
2020/08/25 ADR:ì©lªÑ=1:5 ,1/5=0.20 2023/03/13 ADR:ì©lªÑ=1:25, 1/25=0.04
¤µ¤Ñªº¥½L»ù=0.571*5=2.855¬ü¤¸
ú³°Ó¥Ø¼Ð»ù²z½×¤W¬°: 3*5 ~ 4.5*5=15~22.5¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/13 ¤W¤È 09:51:21
²Ä 6039 ½g¦^À³
|
ìªÑ¼Æ*0.04
¦¬¨ì²°T ¤µ¤Ñ¥Í®Ä
¦³ºâ¿ù¶Ü???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/9 ¤U¤È 08:51:17
²Ä 6038 ½g¦^À³
|
ASLN is undergoing a reverse split of 1:5 on March 13
ASLN¦b3¤ë13¤é¶i¦æ1:5ªº¤Ï¦V©î¤À(´î¸ê)
www.nasdaq.com/market-activity/stock-splits
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/7 ¤W¤È 11:52:35
²Ä 6037 ½g¦^À³
|
2023¦~/3¤ë6¤é ¤î ¤wµo¦æ424,870¤dªÑì©lªÑ/(84,974 ¤dªÑADR)
BVF ¶°¹Î¦û9.99%«ùªÑ.¬ù8500¤dªÑADR(1:5)
¥¼¥]§t»{ªÑÅv: ¬ù38,000¤dªÑADR,1A/1B/2A/2B, 1A/1B(004¸Ñª¼)¦û55%)// 2A/2B(003¸Ñª¼)¦û45%
BVF¶°¹ÎÁ`«ùªÑ(§t»{ªÑÅv)¹F¬ù46,500¤dªÑADR, ¦û¥¼¨ÓÁ`µo¦æªÑ20¸U¤dªÑADR(1:5)¬ù23%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/7 ¤W¤È 08:54:40
²Ä 6036 ½g¦^À³
|
ir.aslanpharma.com/static-files/600458ef-6f6c-4770-9d91-5d1e3f8930c7
3¤ë6 ¤é,
»{ªÑÅv10®a¤½¥q(2Ó¶°¹Î)ªº¸Ô²ÓªÑ¼Æ,95%¥H¤W¶°¤¤¦bBVF¶°¹Î.
¥»¦¸¨p¶Ò59,957,865ì©lªÑ/(11,991¤dªÑADR).
¤wµo¦æ424870¤dªÑì©lªÑ/(84,974 ¤dªÑADR)
¥H¤U¦Ê¤À¤ñ°ò©ó¤À¥À¡A¤À¥À¬°¡G(i) ºI¦Ü 2022 ¦~ 6 ¤ë 30 ¤éªº 348,723,365 ªÑ¤wµo¦æªÑ²¼¡A ³o¬Oµo¦æ¤H¦b¦VÃҨ鴣¥æªº 424B5 ªí®æªº©ÛªÑ»¡©ú®Ñ¤¤©ÜÅSªº¤wµo¦æªÑ¥÷Á`¼Æ¡A¥H¤Î ¥æ©ö©eû·|©ó 2022 ¦~ 9 ¤ë 30 ¤é¡A(ii) 59,957,865 ªÑ¦]µo¦æ¤Hªº¨p¶Òµo¦æ¦Óµo¦æªº ©ó 2023 ¦~ 2 ¤ë 24 ¤éÃö³¬¡A¦p 2023 ¦~ 2 ¤ë 24 ¤é¦V¬ü°êÃÒ¨é¥æ©ö©eû·|´£¥æªº 6-K ªí®æ¤¤ªºµo¦æ¤H³ø§i¤¤©Òz (iii) 16,190,000 ªÑ³ø§i¤H¾Ö¦³ªº¬Y¨Ç¹wª`¸ê»{ªÑÅvÃÒªº¬ÛÃöªÑ¥÷¡]¦p¾A¥Î¡^¡C
The following percentages are based on a denominator which is the sum of: (i) 348,723,365 Shares outstanding as of June 30, 2022, which is the total number of Shares outstanding as disclosed in the Issuer¡¦s Prospectus on Form 424B5 filed with the Securities and Exchange Commission on September 30, 2022, (ii) 59,957,865 Shares issued in connection with a private placement by the Issuer that closed on February 24, 2023 as reported in the Issuer¡¦s Report of Foreign Issuer on Form 6-K filed with the SEC on February 24, 2023 and (iii) 16,190,000 Shares underlying certain Pre-Funded Warrants owned by the Reporting Persons, as applicable. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/6 ¤U¤È 10:34:44
²Ä 6035 ½g¦^À³
|
¬ü°ê¤H¤w¤W¯Z¤F
ªÑ»ùªÑ¼Æ¦p |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2023/3/6 ¤U¤È 07:31:26
²Ä 6034 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/6 ¤U¤È 05:59:07
²Ä 6033 ½g¦^À³
|
¤µ¤Ñ½L«e½L¡A
ªÑ»ùÁÙ¬O¨SÅÜ¡Aºû«ù0.7575¤¸
´î¸ê¤é´ÁÁÙ¨S¨ì¶Ü¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤U¤È 01:34:08
²Ä 6032 ½g¦^À³
|
°²³]°ò缐EASI28
EASI90 ,¥¼³Q²M°£ªÌ³Ñ2¡P8¤ÀªºEASI
¥¼¹FIGA01,§Y¦³2/3Ó³¡¦ì¥¼§¹¥þ²M°£¡C
¨C¤@³B¬O¤@¤À©Î¤G¤ÀªºªºEASI
°ò¥»¤W¦³9¡ã16¶gªº®É¶¡¨Ó§¹¥þ²M°£¡AÀ³¸Ó«Ü®e©ö¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤U¤È 01:19:08
²Ä 6031 ½g¦^À³
|
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
6¤Hªº400mg ²Õ, EASI90 °ª¹F67%
¤@¯ë¤T´Á16¶gªºÁ{§ÉÀø®Ä
¹FEASI90 ªº¤ñ²v§C©óIGA0,1
1.Dupilumab ¤T´Á ¤GÓÁ{§É:
IGA0/1 38%/36% EASI90 36%/30%
www.nejm.org/doi/full/10.1056/nejmoa1610020
2.Lebrikizumab
IGA0/1 43%/33.1% EASI90 38.1%/30.2%
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
IGA0,1: °ò½u©Û¦¬IGA0,1=4 ©Î3.
§¹¥þ²M°£=IGA0 ¨ä¤¤¦³¤@³¡¦ì¨S§¹¥þ²M°£,IGA=1 ¨ä¤¤¦³¤G³¡¦ì¨S§¹¥þ²M°£,IGA=2 ¨ä¤¤¦³¤T³¡¦ì¨S§¹¥þ²M°£,IGA=3 ¨ä¤¤¦³¥|³¡¦ì¨S§¹¥þ²M°£,IGA=4
¨Åé¦@¤À¥|¿³¡¦ì.
IGA0,1,ªí¥Ü0©Î1Ó³¡¦ì©|¥¼§¹¥þ²M°£.
------------------------------- EASI¿Å¶q¨t²Î ¥þ¨¥ç¤À¥|Ó³¡¦ì, ¨CÓ³¡¦ì³Ì°ª18¤À,(¦³¼ÆÓ¤p¶µ¥Ø: ¬õ¯l...)
---------------------------------
IGA0/1 38%.36% EASI90 34%/32%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/3/6 ¤U¤È 12:44:44
²Ä 6030 ½g¦^À³
|
IGA 0/1¥NªíÁ{§Éªv·U²v¡A 004¦b1b 8week Mitt 400mg¹êÅç²ÕVS¹ï·Ó²Õ¬°14%:15% 600mg¹êÅç²ÕVS¹ï·Ó²Õ¬°44%:15% ©Ò¥H¤Ñ©R¤j¤~¥Î44¢H§@¬°IGA 0/1ªº´Á«ÝÈ Dupilumab¬O¦b²Ä12 week¤~¹F¨ìÅãµÛ ¹ï¤ñ©óLeb. 2b 8week IGA 0/1¹êÅç²ÕVS¹ï·Ó²Õ¬°31%:5%¡]26¢H¡^ 2b 16week IGA 0/1¹êÅç²ÕVS¹ï·Ó²Õ¬°45%:15%¡]30¢H¡^ IGA 0/1»Ýn®É¶¡¨Ó±À¶i¡Kµ¥«ÝÁ{§É¼Æ¾Ú¨Ó¸Ñµª
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤W¤È 11:55:10
²Ä 6029 ½g¦^À³
|
www.globenewswire.com/news-release/2022/01/05/2361507/0/en/Connect-Biopharma-Reports-Detailed-Positive-Dataset-from-the-Global-Phase-2b-Trial-of-CBP-201-in-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis.html
CBP201 2B IGA0,1
28.1% VS 10.7% (¬Û®t17.4%)
°ò½u¦ôEASI25
2.Dupilumab ¤T´Á IGA0,1
¤GÓ¤T´Á©M¹ï·Ó²Õ¬Û®t28% (38%/10%) (26%/8%)
3.Lebrikizumab mmm ¤T´Á¨âÓÁ{§ÉIGA0,1 www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
AdvO.1 43%VS12.8%(29.6%) ADVO.2 33.1%VS12.9%(22.2%)
°ò½u: EASI28.8/29.7
°ê»Ú¤W¬Ýªº¬O©M¹ï·Ó²Õªº¬Û´î®t²§.¤Îµ´¹ïªº¤ñ²v
CBP201 ªº¤¤°ê2bÁ{§É¤v°µ§¹,IGA0,1 ¥ý«e®t¤£¦h, ¥Ø«e¶Ò¤£¨ì¤T´Á¸êª÷¬O¨Æ¹ê.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/6 ¤W¤È 11:34:06
²Ä 6028 ½g¦^À³
|
CNTB CBP2012b
IGA0,1 29%vs10%(¹ï·Ó组)¡A¬ù¬°2.9¿
ASLAN004¦p¸¨¦b
IGA0,1 44%vs15%(¹ï·Ó组)¡A¬ù¬°2.93¿ ¹ïCNTB¦³¦óÀu¶Õ¦s¦b¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤W¤È 11:12:28
²Ä 6027 ½g¦^À³
|
¤½¥q9/15¤é¡BR and D day
°²³]°ª©ódupilumab 8%
À³¬O¦X²z预´Á¡D
¤½¥q¤@ª½±j½Õ³s¦X¤G½uAD¡B¥i¦¨¬°¤@½uº¿ï¡D
©Ò¥H¸¨¦bIGA0,1=44%/15%(¹ï·Ó组)
¾÷·|«D±`¤j¡D
¸¨¤JCBP201§CÀø®Ä组¡B«D±`§C¡D
§_«hBVP¤ÎK ¤½¥q¡B¤£·|¥æ2000¸U¬ü¤¸¡D¶R¶i23%¤äªÑ¡B联¦X8000¸U¬ü¤¸ªº»{ªÑÅv§Q¡D
³oºØ¤½¥q«Ü¼F®`ªº¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/3/6 ¤W¤È 10:32:25
²Ä 6026 ½g¦^À³
|
¥Ø«e¥«³õµ¹ASLN ªº¥«»ù¡B´N¦p¦PCNTB
¥¼¨Ó004¸Ñª¼ªºÀø®ÄY¦pCBP201, ¥iÃø¶Ò¤T´Á¸êª÷¡D
½Ð±Ð¤Ñ©R¤j¤j ´N±z¤â¤W²{¦³¸ê°T ¥¼¨Ó004¸Ñª¼ªºÀø®ÄÀu©óCBP201 ªº¾÷·|¬O¦p¦ó???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤W¤È 09:37:39
²Ä 6025 ½g¦^À³
|
BVF ¤½¥q¶ÈºÞ²z49»õ¬ü¤¸ªº¤p¤½¥q¡D
ASLN³Q¨ÖÁʪºÁͶդ£ÅÜ!(³Ì¥i¯à状ªp)
¦³¤组¥¼¸Ñª¼ªº¼Æ¾Ú²V¦b¤@°_¡B¹ê¦b¤£ª¾³Ì¦n¤@组·|°ª¨ì¨º¸Ì¡D
Lebrikizumab 2b
IGA0,1
Q2Wx250mg=44% Q4Wx250mg=33% ¹ï·Ó组=15% ¥H¤W¥¼¸Ñª¼ªº¼Æ¾Ú²V¦b¤@°_¡B¹ê¦b¤À¤£¥X¡D
¥»¦¸¨p¶Ò0.89¬ü¤¸¡D ASLN¥«È8900¸U¬ü¤¸¡D
©MCNTB 7000¸U¬ü¤¸¥«È®t¤£¦h¡D
CNTB CBP2012b
IGA0,1 ¶È 29%vs10%(¹ï·Ó组)
EASI75=47%
¥Ø«e¥«³õµ¹ASLN ªº¥«»ù¡B´N¦p¦PCNTB
¥¼¨Ó004¸Ñª¼ªºÀø®ÄY¦pCBP201, ¥iÃø¶Ò¤T´Á¸êª÷¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤W¤È 09:03:18
²Ä 6024 ½g¦^À³
|
BVF is based out of San Francisco.
BVF is a hedge fund with 5 clients and discretionary assets under management (AUM) of $4,920,045,461 (Form ADV from 2022-03-31).
Their last reported 13F filing for Q4 2022 included $2,369,483,196 in managed 13F securities and a top 10 holdings concentration of 45.23%. BVF¡¦s largest holding is MoonLake Immunotherapeutics with shares held of 21,751,284 whalewisdom.com/filer/bvf-inc-il
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/3/6 ¤W¤È 09:03:16
²Ä 6023 ½g¦^À³
|
¼W¸ê¬O¥ÑBVF Partners LP¡BK2 HealthVentures ©M¬Y¨Ç²{¦³§ë¸êªÌ©Ò°^Ämªº ¨Ã¤£¬O³£¥ÑBVF´£¨Ñ... K2 HealthVentures¦b2021¦~¦³´£¨Ñ2000+2500¸U¬ü¤¸ªº¿Ä¸ê¡A³o¦¸¬O¦A¥[½X...
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/3/6 ¤W¤È 08:48:58
²Ä 6022 ½g¦^À³
|
«Øij¡G
1¡B¥¼¶RªÌ¡G³o®a¤½¥q¹L©¹§¢©V¡A«e´º³ô¼~¡A¸ê°T¤£©ú¡A¤£©y¶R¤J¡C 2¡B¤w¶R¬Ý®tªÌ¡G³o®a¤½¥q«ù¦³h¤ß¡A¸ê°T¥i¯à¤£¹ê¡A¬°ÁקK³Ò¯«¶Ë°]¡A¶X¥¼¤U¥«¡A°±·l½æ¥X¡C 3¡B¤w¶R¬Ý¦nªÌ¡GÁa¨Ï¼ÖÆ[¡A¦ý§ë¸ê·sÃĪѡA¥ô¦ó¤½¥q¦b·Nªº±q¨Ó³£¤£·|¬O§ë¸ê¤H¡A»{¯uµû¦ô«ù¦³¡C 4¡B·¥«×¼ÖÆ[ªÌ¡GÄ~ÄòµL·NÃÑ«ù¦³¡Aµ¥Â½µP¬Ýµ²ªG¡A¿é¤F§Oú¡AŤF¦Û¤v¯º¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/6 ¤W¤È 08:45:18
²Ä 6021 ½g¦^À³
|
BVF ¡]¥Í§Þ²£·~ªº§ë¸ê°òª÷¤½¥q¡^¡A¦ûASLNªÑÅv¤w¦¨³Ì¤j¡C
¤@¡B2¤ë©³¨p¶Ò0.8895¬ü¤¸¡þADR ¡]1:5¡^¡A»{ÁÊ2000¸U¬ü¤¸¡A112¡A359¡A550ªÑì©lªÑ¡]22¡A471¡A910ADR¡^x$0.178
¥Ø«e¤wµo¦æ¶q¡]§t¤º¿EÀy¡^¬ù10¸U¤dªÑªºADR¡C
BVF «ùªÑ22471¤dªÑADR¡A¦û22¡P47%¡]³Ì¤jªÑªF¡^ ð¸ê¥»¤½¥q«ùªÑ5364¤dªÑADR¡A¦û5.36%¡]²Ä¤G¤jªÑªF¡^ ²H°¨¿ü¤½¥q«ùªÑ1678¤dªÑADR ¦û1¡P67%¡]²Ä¤¤jªÑªF¡^
¤G¡BBvFªº»{ªÑÅv
¦@¬ù55¡A309¤dªÑADR¡]1:5¡^¡A³Ì°ª»{ÁÊ8000¸U¬ü¤¸
1¡B004 2b ¸Ñª¼¼Æ¾Ú¤½¥¬«á60¤Ñ¤º¡C ¡]1¡^50% ¡A¨Ì1.3¬ü¤¸p»ù¡C»{Áʼƶq¦ô40%¡]1.3/1.63=79.75%,¨Ì³æ»ù¦ô004¦û80%¡A003¦û20%¡^¡A55¡A390x40%=22,156¤dªÑADR
(2)50% ¡AMAX(¨Ì¼Æ¾Ú¤½¥¬«á¤@¬q®É¶¡ªº¥[Åv¥§¡³æ»ùx50%,1¡P3¬ü¤¸¡^
2¡B003 2A ¸Ñª¼¼Æ¾Ú¤½¥¬60¤Ñ¤º¡C ¡]1¡^50%¡A¨Ì1.63¬ü¤¸¡A»{Áʼƶq¦ô10%¡A55¡A390x10%=539¤dªÑ¡AADR¡C ¡]2¡^50% ¡AMAX(¨Ì¼Æ¾Ú¤½¥¬«á¤@¬q®É¶¡ªº¥[Åv¥§¡³æ»ùx50%,1¡P63¬ü¤¸¡^
¥¼¨ÓªÑ¥»ADR´î¸ê«á4¸U¤dªÑ¡C BVF«ùªÑ ¡]¬ù55¡A309+22¡A471/5=11,511¤dªÑ¡]ADR 1:25¡^
11¡A511/40¡A000=28.78%
¥H¤W¸Ñª¼¼Æ¾Ú>=BvFªº¹w´Á¡C¤è·|°õ¦æ»{ªÑÅv¡C
BVF¬O²{¦b¤Î¥¼¨Ó¤@¦~¤º³Ì¤jªÑªF¡A¤w¬O¨Æ¹ê¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/6 ¤W¤È 08:13:32
²Ä 6020 ½g¦^À³
|
³o®a¥»¨Ó´N¬O¥Ö¥]¤½¥q¶BÄF¶°¹Î¡A
¤@¨ÆµL¦¨¡A¥u³Î韮µæ
²{¦b´î¸ê¡A¥¼³qª¾©Ò¦³ªÑªF¡A´N¬O´ÛÄF
2b´Á¤¤¼Æ¾Ú¦pªG¤£¿ù¡Aì©l¤jªÑªF¦p²H°¨¿ü·|¤£À´§ë¸ê¶Ü¡A ´N¬O¦]¬°¹ï¤½¥q°ª¼hªº§@¬°¥¢±æ
¥¼¤½¶}¤§«e»¡ªº¼Æ¾Ú·Án¡A¥i¯à³£¬O¬°»~¾É¤j²³¡A±q¥xÆWÄF¨ì¬ü°êªº¦L«×ªü¤TCEO ªü«i ¡A ³o®a¤½¥q¸Û«H¦³°ÝÃD¨S±Ï¤F¡A§O¦A¬°¥L»¡¸Ü¤F¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gjimmylin10141563 |
µoªí®É¶¡:2023/3/5 ¤U¤È 11:27:16
²Ä 6019 ½g¦^À³
|
¨«¨ì¤µ®É¤µ¤é®Ú¥»°ÝÃD´N¬O±qasln1~3¸Ñª¼³£¥¢±Ñ ±q¦Û¤j¦Û¸ó¸Ø¨ì²{¦b¤´¤@¨ÆµL¦¨¡A±qÀù¯g¥ÎÃħﰵ¥Öª¢¤@´Á¤´¤£²z·Q¡A ¨C¨C½Ð¤ÀªR®v³Û°ª»ù¡A«o¤´©ñ¥ôªÑ»ù¶^¸¨¨¦©³¨ì§Ö¤U¥« Á{§É¼Æ¾Ú±q¤£³z©ú¡A¹ï§ë¸ê¤H¸ê°T¤£¹ïºÙ¤£¤Íµ½¡A «Øij¤£n¹L«×¼ÖÆ[¤ñ»ù¨ä¥LÃļt¡A³o®a¤½¥q¤j¤á¬O¨S¦bÅUªº µ¥¤HÄ@·N¦¬ÁʦӤw
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/3/5 ¤U¤È 10:46:46
²Ä 6018 ½g¦^À³
|
Ó¤H¬Ýªk¡G
¤@¯ë§ë¸ê¤HÁ`·|»{¬°´î¸ê¬O¤£§Qªº¡A¦ý¨ä¹ê´î¸ê·í¤U¡AªÑ´î»ù¼W¡AÁ`»ùÈÁÙ¬O¤£Åܪº¡F nÃö¤ß¯d·Nªº¬O¥H«áªºµo®i¡F ¥xªÑ´î¸ê«á¨götªº®×¨Ò¤£³ÓªTÁ|¡A¨Ò¦p°ê¥¨¡BÛ¸¡B¥ß³Í⋯³£¬O¥¿±ªº®×¨Ò¡C
¨Æ±¡Á`¬O¦³È±oÆ[¹îªº¦a¤è¡A´²¤á©Ò¯à°µªº¡ã´N¬OÆ[¹î¡ABVFªº§ë¤J§Y¬O¡I ±¯½´¦¶}«e´N¬ORiskªº®£Äß¡A´¦¶}«áªÑ»ù¤]³\¤w¹L¸U«¤s¡I §à¾Ü¨S¦³¹ï¿ù¡A«eµ{¦¹¥h¨â¯í¯í¡AºÝ¬ÝÓ¤H³y¤Æ¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/3/5 ¤U¤È 09:50:35
²Ä 6017 ½g¦^À³
|
³o¬q®É¶¡¨ÇÁÂÁ¤j®a¦b¦¹ª©¤W¤À¨É«Ü¦h·Qªk¸òÆ[ÂI¡A´Ý§ÔªºX«i°µ¤F´î¸êµLºÃ¬O¹ï¥xÆWì©l§ë¸ê¤H³Ì¤jªº¶Ë®`(¥xªÑ«ù¦³¦Ü¤µÁY´î¤F1/25)¡A§ë¸ê¥»¨Ó´N¬O¿éŦU¦³¡A¬ÕÁ«¦Ût¡A©Ò¥H¤]¨S¬Æ»ò¦n©ê«è;³Ì«á¤@ÂI¤p¬Ýªk¤À¨É¡A¦pªG¨S¦³¥¿¦V´Á¤¤¼Æ¾Ú¡Aªí©w7¤ë¸Ñª¼n¦nªº¾÷·|¤£°ª¡A³Ì«á§Æ±æ·s·à¤Í³£¯à¥þ¨¥þ°h¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/3/5 ¤U¤È 07:13:30
²Ä 6016 ½g¦^À³
|
¬Ý«e±ª©¤Í´£¨ìºÞ²z¶O §Úµo²{§Ú¨È·à±d¥h¦~¨S¸ò§Ú¦¬ºÞ²z¶OC «e¦~¦³¦¬¡A¥h¦~¨S¦¬ ¬O¦]¬°¥h¦~¶^¤Ó¦h©ó¤ß¦³·\¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/5 ¤U¤È 12:15:03
²Ä 6015 ½g¦^À³
|
¤Ñ©R¤j ±À½×«Ü¦X²z¡A¥X¿úªº¬O¦Ñ¤j¡A¦b«O±K¨óij¤UÀ³¸Ó¥i¥H¬Ý¨ì¥¼§¹¦¨ªº¤Gb¼Æ¾Ú¡A¼Æ¾Ú¤£¨Î·F¹À¥X¿ú»{ªÑ¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/5 ¤W¤È 10:54:41
²Ä 6014 ½g¦^À³
|
¥xÁÞ¤j¡A Á׶}3¤ë26¤éªº¤U¥«·ÀI¡C
n¶}ªÑªF·|¶·¤½§i¤@Ó¤ë¡C
⋯⋯ ¤ß±o¡G
BVF ¥i¯à¬Ý¹L¥Ø«e¤x¦³¡A§¹¦¨16¶gªvÀøªº¥¼¸Ñ¨w¼Æ¾Ú¡]¬ù80%¡^¤~·|¥ý»{ÁÊ2000¸U¬ü¤¸ªºADR¡C¡]2¤ë27¤é§¹¦¨¡^
¤½¥q¤]¥²´£¥X¥i²Õªº¼Æ¾Ú¹w´ú¡A¤~¦³¥t¥~8000¸U¬ü¤¸ªº»{ªÑ¿ï¾ÜÅv¡C
1.3/50%x5=13¬ü¤¸¡]¤½¥q»{¬°2b¸Ñª¼«á¡A¥i¯à¹F¨ìªº³Ì§C¥§¡¥«»ù¡^
13¬ü¤¸x4¸U¤dªÑADR=5.2»õ¬ü¤¸¡]2b¸Ñª¼¦¨¥\³Ì§C¥«È¡^
2ú³°ÓADR¥Ø¼Ð»ù15¡ã22.5 ¶Ò¸ê»ù=¥Ø¼Ð»ùx80% ¡×12¡ã18¬ü¤¸ ¥«È4.8»õ¬ü¤¸¡ã7.2»õ¬ü¤¸¤§¶¡¡C
¥Ñ¥H¤W¤ÀªR¡A2b¸Ñª¼³Ì¨ÎQ2w*400mg ²ÕªºÀø®ÄIGA0,1À³¸Ó¸¨¦b44%vs15%¡]¹ï·Ó²Õ¡^¡C
Y¤j´T©Ô¤WIGA0,1 50%-60%¡A¤~¦³©Ô°ª¥Ø¼Ð»ùªº¾÷·|¡C
IGA0¡A1 ¤£¦p¹w´Á¡ABvF¤£·|»{2000¸U¬ü¤¸ADR¡C¤G½uAD¤]·|¥[³t¶i¦æ¡A¤G缐Á{§É¸ê°T¤x40¤Ñ¥¼§ó·s¤F¡C
¤G½uªº°ÝÃD¡A¥i¯à·|¿z¿ï±¼¬Æ¦hªº«D¶Ç²ÎAD¡]«D¤G«¬ª¢¯g¡^±wªÌ¡C
¥H¤WÓ¤HÆ[¹î¤ß±o¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³ßô10031624 |
µoªí®É¶¡:2023/3/5 ¤W¤È 10:25:25
²Ä 6013 ½g¦^À³
|
ºI¿ý·à¤lªº¤½§i«nÃöÁä ½Ð°Ñ¾\¤U± ¼¯®Ú¤j³q银¦æ¡AN.A¡C 麦}逊¤j¹D383号¡A11楼 纽约¡A纽约¡A电话¡G10179 ª`·N¡G¦s¦«ú«证¶°团 邮½c¦a§}¡GDR _ Global _ CSM@jpmorgan.com ¡]¤G¡^ ASLAN Pharmaceuticals Limited ²H马锡¤j¹D3号¡A18层¡A ¦Ê¦~纪©À¶ð¡A ·s¥[©Y039190 ª`·N¡GKiran Asarpota¡Aº®u财务©x 电¤l邮¥ó¦a§}¡Gkiran.asarpota@aslanpharma.com ªþ赠电¤l邮¥ó¦Ü¡Gben.goodger@aslanpharma.com ¥H电¤l«H®§传°e¤è¦¡发°e³qª¾¡A应视为¦b发¥ó¤H开©l¦V¤Wz电¤l邮¥ó¦a§}发°e³qª¾¡]¦p发¥ó¤Hªº记录©Ò¥Ü¡^时¦³®Ä¡A§Y¨Ï预©w¦¬¥ó¤H¦b¥H¦Zªº¤é´Á¨ú¦^该邮¥ó¡B¥¼¯à¨ú¦^该邮¥ó©Î¥Ñ¤_¨ä¥¼¯à«O«ù«ü©wªº电¤l邮¥ó¦a§}¡B¥¼¯à«ü©w´À¥N电¤l邮¥ó¦a§}©Î¥X¤_¥ô¦ó¨ä¥Lì¦]¦Ó¥¼¯à¦¬¨ì该³qª¾¡C ²Ä2.06节¡C¦Û«O¦s¤Hº¦¸«Å¥¬¤§¤é°_¡A¨C¥÷ADS©Ò¥NªíªºªÑ¥÷数¶q应从¡§5¡¨×§ï为¡§25¡¨¡C ²Ä2.07节¡C发®i¦¨ªG评¦ôªí®æ²Ä¡]5¡^´Ú²Ä¤G¥y¥H¤Î©Ò¦³©|¥¼执¦æªº发®i¦¨ªG评¦ô×¥¿¦p¤U¡G «O¦s¤H©Î¨ä¥ô¦ó¥N²z¤H§¡¤£对ADS©MADRªº«ù¦³¤H©Î¨ü¯q©Ò¦³¤H¤£¿í¦uÓì¥Îªº税ªk¡B规则©M/©Î条¨Ò©Óü®责¥ô¡C尽ºÞ«O¦s¤H¦³权n¨D现¥ô©M«e¥ô¨ü¯q©Ò¦³¤H¥I´Ú¡A¦ý«O¦s¤H¡]¥H¤Î©Ò¦³«e¥ô«ù¦³¤H¡^©Ó认¦}¦P·N¡A«O¦s¤H没¦³úå务n¨D现¥ô©Î«e¥ô¨ü¯q©Ò¦³¤H¤ä¥I¥»´Ú©Ò规©wªº¤í´Ú¡C ²Ä2.08节¡C发®i¦¨ªG评¦ôªí®æ²Ä¡]5¡^¬q²Ä9¥y¥H¤Î©Ò¦³©|¥¼执¦æªº发®i¦¨ªG评¦ô×¥¿¦p |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/5 ¤W¤È 10:04:31
²Ä 6012 ½g¦^À³
|
·PÁ¤ѩR¤j Pica¤j»¡©ú ªk³Wªº¨Æ±¡n¾é¸Ñªº¤H¤~À´¡A¶}Ó¸³¨Æ·|´N¨M©w¡A¥¼§K¤Ó¹L±MÂ_¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2023/3/5 ¤W¤È 08:52:42
²Ä 6011 ½g¦^À³
|
¥u¦³ÁÈ¿ú®É¡A¤~·|¥Î¬Õ¾l°tªÑ¡AÅýªÑªFªºªÑ¼Æ¼W¥[¡AªÑ»ù°§C¡A°§C¶RªÑªºªùÂe¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/5 ¤W¤È 08:51:16
²Ä 6010 ½g¦^À³
|
¥¼¨Óªº2¸UADR¡]1:25¡^¡ABVF¡A¥i¥ý»{ªÑ¬ù1¸UªÑ¡]1.3*5=6.5¬ü¤¸/1.6*5=8¬ü¤¸©Î¥§¡ªÑ»ùx50%°ª»ùªÌ¡^¡C¶Ò8¤d¸U¬ü¤¸¡C
¥t¥~¬ù1¸UªÑ2b¸Ñª¼«á¶Ò¸ê¥Î¡C
©Mì©lªÑªFµLÃö¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2023/3/5 ¤W¤È 08:47:17
²Ä 6009 ½g¦^À³
|
¥x¿}¤j¡A ¼W¸êÀ³¸Ó¬O§ä¤H¤J¸ê¡AµM«áµ¹¥LªÑ²¼¡C ¸ò§Ú̳o¨Ç¦ÑªÑªFµLÃö¡C §Ú̪ºªÑ¼Æ´N¬O³Ñ1/5¦Ó¥H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/5 ¤W¤È 08:31:57
²Ä 6008 ½g¦^À³
|
¤Ñ©R¤j ¥Ø«eÁ`µo¦æ¶q10¸U¤dªÑ ADR ÁY¬°2¸U¤dªÑADR,¥¼¨Ó·|¦A¼W¸ê¨ì4¸UªÑADR(100¸U¤dªÑì©lªÑ)¡A¥¼¨Ó¼W¥[4¸UªÑ¤j®a«ùªÑ昰§_¨Ì¤ñ²v¼W¥[¡H ¤]´N¬O¤QªÑÅܦ¨¨âªÑ¡A¦AÅܦ¨4ªÑ¡C ¥Ø«e¦³¤H«ùªÑ¯uªº´î¤Ö¦Ê¤À¤§80¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/5 ¤W¤È 08:04:18
²Ä 6007 ½g¦^À³
|
BVF ¤½¥qªº¨p¶Ò³æ»ù0.178¬ü¤¸/ì©lªÑ ,ADR(1:25) ¦¨¥»4.45¬ü¤¸.
*** purchase price of $0.178 per Ordinary Share
ADR ,1:25
0.178*25=4.45¬ü¤¸------ BVF ·sªºADR¦¨¥»
-------------------------------------------------------------------- ASLAN Pharmaceuticals Announces Private Placement On February 24, 2023, ASLAN Pharmaceuticals Limited (the ¡§Company¡¨) entered into a Unit Purchase Agreement (the ¡§Purchase Agreement¡¨) with fund entities affiliated with BVF Partners L.P. (collectively, ¡§BVF¡¨) and the other purchasers named therein (the ¡§Purchasers¡¨), pursuant to which the Company agreed to sell to the Purchasers, in a private placement offering, an aggregate of (i) 112,359,550 ordinary shares, par value $0.01 per share (the ¡§Ordinary Shares¡¨), and (ii) pre-funded warrants (the ¡§Pre-Funded Warrants¡¨) to purchase five Ordinary Shares (represented by the Company¡¦s American Depositary Shares (¡§ADSs¡¨)) at a purchase price of $0.178 per Ordinary Share (or the equivalent of $0.89 per ADS) and $0.8895 per Pre-Funded Warrant, respectively, which represents a 15% premium to the ADSs¡¦ ten-day volume-weighted average price (¡§VWAP¡¨) (the ¡§Private Placement¡¨). Each ADS represents five Ordinary Shares. The Private Placement is expected to close on or about February 27, 2023 (the ¡§Closing¡¨), subject to customary closing conditions.
ir.aslanpharma.com/financial-information/sec-filings/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/5 ¤W¤È 06:43:40
²Ä 6006 ½g¦^À³
|
¤w³qª¾ADRªººÞ²z»È¦æ°õ¦æ´î资ªº°Ê§@¡D
¥xÁÞ¤j¡B¥iÀˬd±zªº«ùªÑ¼Æ¬O§_¤w´î80%.
¤U¶g¤@ªºªÑ»ù¶}½L»ù·|¦Û°Ê¸õ°ª5¿¨ì 0.7575*5=3.787¬ü¤¸¡D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/5 ¤W¤È 06:18:27
²Ä 6005 ½g¦^À³
|
ir.aslanpharma.com/static-files/91342411-adb8-4daa-b914-9c495834b780
2023/03/03 ASLN ¤½¥q¸³¨Æ·|³q¹L,¦p¤W
¤½¥q3¤ë3¤é ¤W¶ÇSECªºÀɮסBºô§}¦p¤W |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/3/4 ¤U¤È 10:55:15
²Ä 6004 ½g¦^À³
|
¤Ñ©R¤j ³o»ò«¤jªº´î¸ê°T®§¬°¦ó¤½¥q©xºô¨S¦³¤½§i¡AªÑªF¤]¨S¦³¦¬¨ì¶l¥ó§i¤§¡A·|¤£·|¬O°²°T®§¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/3/4 ¤U¤È 09:26:37
²Ä 6003 ½g¦^À³
|
¬Ý¨Óú¶O®É¶¡³£¤£¤j¬Û¦P §Úªº¦b11¤ë¦hú¤F4¤d¦h¬üª÷ ¦³¹Ú³Ì¬ü¡AÄ~Äò°µ¹Ú§a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/3/4 ¤U¤È 09:07:14
²Ä 6002 ½g¦^À³
|
§ÚªººÞ²z¶O10¤ë¤~ú¡]¤¸¤j¡^ ¨S¯S§Oª`·N¤°»ò®ÉÔµ²ºâªº... «ÂIÁÙ¬O2bªº¼Æ¾Ú¯à¤Ï¬M¦h¤Ö»ùÈ¡A1¡G5 1¡G25 ¤À¥ÀÅܤp¦Ó¤w ad¬ãµo¤¤ªºÃĪ«¹ê¦b«Ü¦h¡A¦³³»¦y¼Æ¾Ú¤~¦³°ª»ùÈ¡A ¶q¤O¦Ó¬°¡AYı±o«e´º¤£©úªº¡A½æ¤@½æ¤]¦w¤ß...
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¾ð10152786 |
µoªí®É¶¡:2023/3/4 ¤U¤È 08:37:54
²Ä 6001 ½g¦^À³
|
¤µ¦~ªºADSªººÞ²z¶Oªºµ²ºâ¤é´Á¬O2023/3/2¡A©Ò¥HºÞ²z¶O¨S¦³¬Ù¨ì³á¡I ¥¿½T¨Ó»¡¡G©ó2/3¥ýµ²ºâ¥¨¶qºÞ²z¶O¡B©ó3/3¤§«áªÑ²¼¼Æ¶q³Ñ¡G1/5 ³o¯uªº«ÜÁV¿|ªº·Pı |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/3/4 ¤U¤È 07:58:27
²Ä 6000 ½g¦^À³
|
³o¼Ë¤@¨Ó¡A¤µ¦~ªºADSªººÞ²z¶O ¥i¥H¬Ù«Ü¦h¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/3/4 ¤U¤È 07:45:14
²Ä 5999 ½g¦^À³
|
¤W¦¸¦]004 1b¸Ñª¼¼Æ¾Ú¤£¨Î¡A
ªÑ»ù±q±q3.25¤U¶^¨ì1¬ü¤¸¥H¤U¡A
¥B«ùÄò¹F§Ö1¦~¡A±Á{´î¸ê©Î¤U¥«¦M¾÷¡A ´Á¤¤¨ÃµL¤j¤O±ÏªÑªº§@¬°
³o¦¸´î¸ê8¦¨¡AªÑ»ù¦^¨ì3.79¤¸¡A ¦pªG7¤ë¥÷004 2b¸Ñª¼¤S¥X·N¥~¡A §Ú»{¬°¤S·|«ºt1b¸Ñª¼ªº¤U³õ¡A
±q¦¹§¹¥þ°h¥X¥Í§Þ¥«³õ¡A
³Å«i¥»¨Ó´N¬O¤@ÓµL¯à¡A¥u·|¥X±i¼Lªº¤H¡A³Ì°_½X¥L¤wÄF±o¹S³Ò¡A
§Ú»{¬°¨È·à±d¥»¨´N¬OÓ¯º¸Ü¡A ¤ñ¦X¤@fb825³£¤£¦p¡A°_½X¥L¦³°ê»Ú±ÂÅv¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2023/3/4 ¤W¤È 09:29:19
²Ä 5998 ½g¦^À³
|
¦p¦¹ªº¸Ü Ó¤Hªº´¢´ú´N¦h¾l¤F ÁÂÁ©R¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/4 ¤W¤È 09:29:00
²Ä 5997 ½g¦^À³
|
ASLAN Pharmaceuticals Announces Private Placement On February 24, 2023, ASLAN Pharmaceuticals Limited (the ¡§Company¡¨) entered into a Unit Purchase Agreement (the ¡§Purchase Agreement¡¨) with fund entities affiliated with BVF Partners L.P. (collectively, ¡§BVF¡¨) and the other purchasers named therein (the ¡§Purchasers¡¨), pursuant to which the Company agreed to sell to the Purchasers, in a private placement offering, an aggregate of (i) 112,359,550 ordinary shares, par value $0.01 per share (the ¡§Ordinary Shares¡¨), and (ii) pre-funded warrants (the ¡§Pre-Funded Warrants¡¨) to purchase five Ordinary Shares (represented by the Company¡¦s American Depositary Shares (¡§ADSs¡¨)) at a purchase price of $0.178 per Ordinary Share (or the equivalent of $0.89 per ADS) and $0.8895 per Pre-Funded Warrant, respectively, which represents a 15% premium to the ADSs¡¦ ten-day volume-weighted average price (¡§VWAP¡¨) (the ¡§Private Placement¡¨). Each ADS represents five Ordinary Shares. The Private Placement is expected to close on or about February 27, 2023 (the ¡§Closing¡¨), subject to customary closing conditions.
ir.aslanpharma.com/financial-information/sec-filings/
2/24¤W¶Ç¬üSECªº¨p¶Ò¸ê®Æ¡B¦³ª`©úì©lªÑ¡B¤ÎADR³æ«K¡B¤Î5´«1ªº´«ªÑ¤ñ¨Ò¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2023/3/4 ¤W¤È 09:15:05
²Ä 5996 ½g¦^À³
|
¥H¤W¬OÓ¤H´¢´ú ¦pªGadr´î¸ê«á ¿ï¾ÜÅv»ùÁÙ¬O1.6 ¥u¯à»¡¤½¥q¯Ê¸êª÷ ¥u¯à¥ô°Ñ»P¶Ò¸êªÌ®_¨î
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/4 ¤W¤È 09:10:12
²Ä 5995 ½g¦^À³
|
¤§«eASLN¹ï¥~¶Ò¸ê¡B³æ»ù·|¦P®Éñì©lªÑ¤ÎADR³æ»ù¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2023/3/4 ¤W¤È 09:07:32
²Ä 5994 ½g¦^À³
|
¦pªGadr ¿ï¾ÜÅv»ù®æ´î¸ê«áÁÙ¬O1.6 BVF ·|Áȫܤj ¦P®É¤]·t¥Ü ¤U¶g¤@ªÑ»ù·|¥Ñ3 ÂI¦h©¹ 1.6 ¤U¦æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2023/3/4 ¤W¤È 08:56:22
²Ä 5993 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j BVF 1.6 ¿ï¾ÜÅvªº»ù®æ ¬O¤£¬O¤]n¼¥H5 ¦¨¬°8 Áâ¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/4 ¤W¤È 08:42:27
²Ä 5992 ½g¦^À³
|
´î¸ê«á,
¥¼¨Ó³Q¨ÖÁÊÁ`»ùȤ£·|ÅÜ
¨é°Óªº¥Ø¼Ð»ù¥Ñ¥Ø«e³Ì°ª4.5¬ü¤¸¡A¦Û°Ê¤Wº¦¦Ü22.5 (4.5*5=22.5)¬ü¤¸
ªø´Á´N¤£©ö¶^¦^¤@¤¸¥H¤U,³Q¨ÖÁÊ«e¤£·|¦³¦]ªÑ»ù§C©ó¤@¬ü¤¸³W«hªº¤U¥«·ÀI. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/4 ¤W¤È 08:14:38
²Ä 5991 ½g¦^À³
|
ASLN ADRªÑ¼Æ´î80%,
¥Ø«eÁ`µo¦æ¶q10¸U¤dªÑ ADR ÁY¬°2¸U¤dªÑADR,
¥¼¨Ó·|¦A¼W¸ê¨ì4¸UªÑADR(100¸U¤dªÑì©lªÑ)
ªÑ»ù¤U¶g¤@¶}½L»ùÀ³¬°¤µ¤é¦¬½Lªº5¿ 0.7575*5=3.79¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/4 ¤W¤È 08:03:35
²Ä 5990 ½g¦^À³
|
SECTION 2.06. Effective on the date first announced by the Depositary, the number of Shares represented by each ADS shall be amended from ¡§five¡¨ to ¡§twenty-five¡¨.
ADRº¦¸«Å¥¬¤§¤é°_¥Í®Ä¡A¨C¥÷ ADS ©Ò¥NªíªºªÑ¥÷¼Æ¶qÀ³¬° ¥Ñ¡§¤ªÑ¡¨×§ï¬°¡§¤G¤Q¤ªÑ¡¨¡C
ir.aslanpharma.com/static-files/91342411-adb8-4daa-b914-9c495834b780
2023/03/03 ASLN ¤½¥q¸³¨Æ·|³q¹L,¦p¤W
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/2 ¤W¤È 10:47:55
²Ä 5989 ½g¦^À³
|
¥Ñ2/24¨p¶Ò±À¡G
§¹¦¨2A·§©À©ÊÁ{§É¡A¸Ñª¼¦¨¥\«á»ùÈ¡G
ASLAN003ªº»ùȼW¥[1.63-1.3=0.33¬ü¤¸¡þªÑ
0.33x20¸UªÑADR=6600¸U¬ü¤¸ªº¥«È¡A§¹¦¨60¤Hªº2AÁ{§É«á¦¨¥\«áªº³Ì§C¥«È¡C
¤@¤@¤@¤@¤@¤@ 2023-02-24 ASLAN Pharmaceuticals «Å¥¬¥Ñ BVF Partners LP ²oÀYªº 2000 ¸U¬ü¤¸¨p¶Ò°t°â¡A¨Ã¦³¥i¯àÃB¥~Àò±o°ª¹F 8000 ¸U¬ü¤¸
The first tranche of warrants is comprised (i) 50% of purchase warrants that are exercisable upon issuance and until sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price of $1.30 per ADS and ¤@¤@¤@¤@ (ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price based on the higher of $1.30 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data.
ii) 50%ªº购买权证¡A¥u¯à¦bASLAN¤½开«Å¥¬¨ä调¬d¥ì¥¬©Ô¦è单§Üªv疗¯S应©Ê¥Öª¢ªºTREK-AD 2b´Á临§É试验ªº顶线数Õu¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ°ò¤_1.30¬ü¤¸©M¤½开«Å¥¬数Õu¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAP¡]¯S©w´Á¶¡ADR¥§¡»ù®æ¡^ªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C
xxxVWAP¡G¦p¤½¥¬¸Ñª¼¼Æ¾Ú«áADR 10¤Ñªº¥§¡»ù®æ x50% Y¤Wº¦¦Ü¥§¡7¬ü¤¸¡A«h7x50%=3.5¬ü¤¸¨CªÑADR°µ¬°»{ÁÊ»ù¡A«D1.3¬ü¤¸¡C ¤@¤@¤@¤@ The second tranche of warrants is similarly comprised (i) 50% of purchase warrants that are exercisable upon issuance until sixty days after the public announcement of topline interim data from ASLAN¡¦s planned Phase 2 proof of concept trial investigating farudodstat at an exercise price of $1.63 per ADS and ( ¤@¤@¤@ ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of topline interim data from ASLAN¡¦s planned phase 2 proof of concept trial investigating farudodstat at an exercise price based on the higher of $1.63 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data.
ii¡^50%ªº购买权证¡A¥u¯à¦bASLAN计¦Eªº调¬dfarudodstatªº²Ä¤G阶¬q·§©À验证试验ªº顶线¤¤´Á数Õu¤½¥¬¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ为1.63¬ü¤¸©M数Õu¤½¥¬¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAPªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/3/2 ¤W¤È 10:35:27
²Ä 5988 ½g¦^À³
|
²æ¾vªvÀø120»õ¬ü¤¸¥«³õ¡]2028¦~¡^ µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/6/15 ¤U¤È 10:08:55 ·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/6/15 ¤U¤È 09:47:22²Ä 5390 ½g¦^À³ ²æ¾vªvÀø¥«³õ¤ÀªR
www.coherentmarketinsights.com/market-insight/alopecia-treatment-market-1847 ¥_¬ü36»õ¬ü¤¸/¥þ²y87»õ¬ü¤¸¡]2021¦~¡^¡A¦~¦¨ªø²v5¡A3% ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/6/15 ¤U¤È 10:12:43²Ä 1 ½g¦^À³ º¤ä¤fªA¨rÀYÃÄ ¢Ô¢Ò¢Ï§åã
2022/06/15 05:30 ¡e½sĶ©Pi¨Z¡þºî¦X³ø¾É¡f¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¤Q¤T¤é§åã¬ü°ê»sÃĤ½¥q¡u§¨Ó¡v¬ãµoªº¡u·R·Àª¢¡v¡]Olumiant¡^¥Î¨ÓªvÀøÄY«¶ê¨r±wªÌ¡A¦¨¬°¬ü°ê¨C¦~¹O¤Ê¸U¦W¨ü¡u°«cÀY¡v§xÂZªº¥Ö½§¯f¤Hªº²Ä¤@¤ä¤fªAÃÄ¡C
¶ê¨r¬O¦ÛÅé§K¬Ì¯e¯f¡A¥ô¦ó¦³Åé¤òªº³¡¦ì¬Ò¥i¯à¦¨¬°±w³¡¡A¶Ç²ÎªvÀø¥H§½³¡Ãþ©T¾Jª`®g¬°¥D¡A¥i¨ë¿E¤ò¾v¥Íªø¦ý©ö´_µo¡A¤µ¦~¦b¶ø´µ¥d¹{¼ú¨å§¾x¥X¥Ï¤Ú´x·ªiªº¼v¬P«Âº¸¥v±K´µ¤§©d§Y¬°±wªÌ¡C
¡u·R·Àª¢¡v¥H¡u¤Ú·ç´À¥§¡v¡]Baricitinib¡^¬°¾Ç¦W¤ÎÃĪ«¦¨¤À¡A¥ý¦b¤G¡³¤@¤»¦~ÀòãªvÀøÃþ·Àã©ÊÃö¸`ª¢¡A¤W¤ë¤SÀòãªvÀøªZº~ªÍª¢¦¨¦~««×±wªÌ¡C
¾Ú¹êÅçµ²ªG¡AÄY«¶ê¨r±wªÌ¦@¤@¤G¡³¡³¤H¨ü¸Õ¡A¤À¨C¤éªA¥Î¤G¡B¥|²@§J¤Î¦w¼¢¾¯²Õ¡A¤Ê¤»¶g«á¡A°ª¾¯¶q²Õªñ¥|¦¨ªø¦^¤K¦¨¤ò¾v¡B§C¾¯¶q²Õ¤Ü¤T¢Hªø¦^¤K¦¨¾v¶q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/3/2 ¤W¤È 10:09:03
²Ä 5987 ½g¦^À³
|
¥i§_½Ðª©¤W±M·~ªº¤j¤j´NFarudodstat ¦¨¥\ªº¾÷²v¡A©M¥«³õ³W¼Ò¤ÀªR»¡©ú¤@¤U
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gjimmylin10141563 |
µoªí®É¶¡:2023/3/1 ¤U¤È 11:33:04
²Ä 5986 ½g¦^À³
|
Æ[¹î°Æ«i¥H©¹§@·´N¬OµL¬°¦Óªvªº·®æ¡A¥L¬O¥uµ¥³Q¦¬ÁʶܡH
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/3/1 ¤U¤È 08:26:34
²Ä 5985 ½g¦^À³
|
®É¦Ü¤T¤ë Áö¤£§Æ±æ¡A¤]±o¦Ò¼{³oÓ°ÝÃD n¬O¨p¶ÒÁÙ¬OµLªk§âªÑ»ù±À¤W1¤¸¡A¸Ó¤£·|ÁÙn°f¤À³Î§a §Úı±o¯à§_¤W1¤¸¯uªº«Ü«n¡A³o¤]¬O«H¤ß©Ò¦b ¤jªÑªFÌ¥[ªo°Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/3/1 ¤U¤È 02:10:37
²Ä 5984 ½g¦^À³
|
¦pªGASLN004¦b¸Ñª¼«e¡AÁÙ¦³´Á¤¤¼Æ¾Ú¥i¨Ñ°Ñ¦Ò¡A¨º´N¤Ó¦n¤F¡A¤£µM©Ò¦³ªº¤@¤Á³£¥u¯à¤¤©Ê¬Ý«Ý¡A¦]¨p¶Ò2000¸U¯uªº¨S¬Æ»ò¡A¹ï©ó¤@Ó¤jÃĨӻ¡¡A¬O¤£¦hªº~ |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 601 ~ 700 «h¦^ÂÐ >> |